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Abstract
Obstructive sleep apnea syndrome (OSAS) is a serious medical condition that
occurs during sleep and consists of episodes of complete (respiratory pauses) or partial
obstruction (hypoventilation) o f the upper airway. Approximately 80% of persons
diagnosed with OSAS are prescribed nasal Continuous Positive Airway Pressure
(CPAP) treatment, which has proven to be the treatment of choice for OSAS. However,
noncompliance with CPAP treatment in OSAS patients is a widely recognized problem,
and many persons refuse CPAP as a treatment option or fail to use it reliably.
Investigations o f CPAP use in OSAS patients have generally found that nightly use
averages less than five hours. Few interventions have been scientifically evaluated for
improving CPAP compliance. The current study evaluated a method of introducing
OSAS patients to CPAP prior to the administering CPAP titration in the laboratory.
Participants in the treatment groups underwent a 30-minute CPAP habituation trial, with
a range of pressures, prior to the polysomnography with CPAP. It was hypothesized
that the participants who experienced CPAP habituation would have better sleep quality
during CPAP, would be more likely to accept CPAP, and would use CPAP more on a
nightly basis than control participants who experienced the usual laboratory procedures
for introducing CPAP (CPAP education) to OSAS patients. There were no statistically
significant differences for any of the dependent variables between participants who
experienced CPAP habituation and participants who experienced CPAP education.
Men were found to use CPAP 1.61 hours more on a nightly basis than women (p = .03).
This difference is most likely attributable to severity, as men were observed to have an
A+HI that was twice the observed A+HI of women participants. Overall, CPAP
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acceptance and compliance for the complete sample was comparable to what has been
reported in the CPAP treatment literature.

vi

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Introduction
Obstructive sleep apnea syndrome (OSAS) is a serious medical condition that
occurs during sleep and consists of episodes o f complete or partial obstruction of the
upper airway, which coincides with excessive daytime sleepiness (EDS; Orr, 1997). It
is the most common organic disorder of EDS that is diagnosed in sleep disorders clinics
and is the most common o f the sleep apnea syndromes (Partinen, 1994). Furthermore,
OSAS is the most severe and most common form of sleep apnea/hypopnea syndrome
(SAHS) and can have dire health consequences if not properly managed. Central sleep
apnea is also a serious sleep-related breathing disorder during which repeated
respiratory pauses occur during sleep, presumably due to a loss o f respiratory effort
(White, 1994). Unfortunately, no completely effective treatment for central sleep apnea
has been developed, and the focus of the present review with be on OSAS and its
treatment. Cross-sectional studies indicate that the minimum prevalence of SAHS is at
least 1% (Partinen, 1994). However, the prevalence of SAHS increases with age, and a
recent study of persons aged 30 to 60 years found rates of sleep apnea of 2% for women
and 4% for men (Young et al., 1993). Additionally, these same investigators found that
4% of women and 9% o f men aged SO to 60 had more than 1S apneas per hour asleep
(Young et al., 1993). In persons aged 65 and older, as many as 25% may experience
more than 5 apneas per hour asleep (Kripke & Ancoli-Israel, 1983). Of those diagnosed
with OSAS, it is estimated that 80% are prescribed nasal Continuous Positive Airway
Pressure (CPAP) treatment. Nasal CPAP has proved to be the treatment o f choice for
patients with OSAS due to its great effectiveness in eliminating apnea and normalizing
the sleep architecture (i.e., the composition of sleep; Sullivan & Grunstein, 1994).

1
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In OSAS, episodes of complete obstruction of the upper airway are referred to as
apneas while episodes of partial obstruction are referred to as hypopneas. An episode
of complete (i.e., apnea) or partial airway obstruction (i.e., hypopnea) must last for a
minimum o f 10 seconds and must occur during sleep to be scored as a respiratory event.
However, sleep apneas and hypopneas typically last between 20 and 40 seconds, and
severe events can last up to 120 seconds. These sleep-related respiratory events are
usually accompanied by a drop in available blood oxygen (Sa02) and often by a central
nervous system (CNS) arousal response and an autonomic nervous system (ANS)
arousal response. Such activation of the CNS results in transient arousals from sleep,
and if great enough, complete awakenings. Transient arousals from sleep take the form
of bursts of alpha waves (8-11 cycles per second) lasting between 3 and 14 seconds,
which degrade the overall quality of sleep causing it to be light and discontinuous
(American Sleep Disorders Association [ASDA], 1992). If transient arousals occur at
high rates, the sleep architecture can be markedly altered, with reductions of stages 3
and 4 non-rapid eye movement (NREM) sleep, referred to collectively as slow wave
sleep (SWS) and a reduction o f rapid eye movement (REM) sleep. Large numbers of
transient arousals will also increase stage 1 NREM sleep, which is regarded as
light/transitional sleep. Blood oxyhemoglobin desaturation usually occurs during or
shortly after sleep apneas and hypopneas, with oxygen desaturation below 85% being
considered severe, although desaturations can be as low as 50%.
One important measure of the severity o f OSAS is the number of sleep-related
respiratory events per hour asleep, which is given in the form of the Apnea + Hypopnea
Index (A+HI). The diagnostic criterion for the frequency of sleep-related respiratory
events in SAHS is a minimum o f 5 events per hour asleep; however, significant
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pathology is not thought to occur until there are 10 or more events per hour asleep
(Guilleminault, 1994). Patients suffering from clinically significant symptoms and
sequelae o f OSAS typically will have 20 or more episodes of apnea/hypopnea per hour
asleep. People suffering from severe OSAS may have apneas with arousal as often as
twice per minute, or 120 arousals from sleep per hour (Roth, Roehrs, & Zorick, 1982).
According to the authors of the International Classification of Sleep Disorders-Revised,
in addition to the criterion of an A+HI of at least S per hour asleep, the respiratory
obstructions must be accompanied by one or more of the following: frequent arousals
from sleep that are associated with airway obstruction, bradytachycardia, and arterial
oxygen desaturation that is associated with the sleep-related respiratory events the
(ASDA, 1997). Severity o f OSAS is categorized as mild, moderate, or severe according
to the A+HI, the level o f daytime sleepiness, the severity of oxygen desaturation, the
presence o f cardiac arrhythmias, and the level of impairment in daytime functioning
(ASDA, 1997). In general, the daytime consequences of OSAS are correlated with the
severity o f the apneas (Roehrs, Zorick, Wittig, Conway, & Roth, 1989). Reports of
subjective sleepiness and alertness may vary between patients with similar levels of
objective severity; however, a clinical interview will often reveal unusual sleepiness,
with patients reporting that they fall asleep during a variety of activities (Guilleminault,
1994). Often, the development of sleepiness in OSAS is insidious with patients
presenting for treatment after they have endured symptoms for a number of years (Orr,
1997).
The most common presenting symptom in adults with OSAS is EDS (ASDA,
1997). This symptom may be more evident to persons with OSAS or to observers
because the perception o f sleepiness varies across individuals with reported sleepiness
3
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not always being congruent with objective measures of sleep propensity. The degree of
impairment in daytime functioning is variable and ranges from marked impairment due
to irresistible urges to sleep to only moderate daytime sleepiness, which is usually
unmasked only during periods of low stimulation. Patients with EDS may fall asleep
during low stimulation activities such as watching television or during meetings. In
severe cases o f EDS, patients will report falling asleep involuntarily while eating,
talking, or performing very important activities such as driving. The presence of EDS
can be of particular importance in occupations that require sustained attention, high
levels of concentration, or repetitive tasks (e.g., long-haul truck driver or nuclear power
plant operator). The overwhelming sleepiness experienced by many patients with OSAS
has been shown to result in a higher frequency o f occupational and driving accidents as
compared to the general population (Guilleminault, 1982; Roth, Hartse, Zorick, &
Conway, 1980). Sleep fragmentation and sleep deprivation from OSAS can result in
episodes o f automatic behavior during which the affected person engages in semi
purposeful but inappropriate behavior during brief episodes of involuntary sleep
referred to as microsleeps (Aldrich, 1994). Loud and persistent snoring (i.e., vibration
of the soft palate and posterior faucial pillars due to increased airway resistance in
sleep) is the most common cause of referral for OSAS (Guilleminault, 1994). Snoring
in OSAS patients is often interrupted by silences (absence of airflow), which are
followed by loud snorting or gasping sounds and large body movements when breathing
is resumed (Guilleminault, 1994) If a respiratory event is severe, it is not unusual for
the affected person to raise the upper body and partially sit up in bed at the termination
of the event, and such loud snoring and gross body movements frequently result in the
spouse sleeping in a separate bedroom (Guilleminault, 1994). Other symptoms of sleep
4
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apnea include frequent nocturnal awakenings accompanied by sensations o f choking or
not being able to breathe, reduced energy, significantly reduced sleep onset latencies,
frequent morning headaches, diminished ability to concentrate, mild memory
impairment, and increased irritability from sleep fragmentation and partial sleep
deprivation (Guilleminault, 1994). Additionally, upper airway obstruction is associated
with changes in esophageal and gastric pressures, which produces complaints of
heartburn and acid reflux in some patients with OSAS (Guilleminault, 1994). Nocturia
is a common symptom also with 28% of patients reporting at between 4 and 7 trips to
the bathroom per night (Guilleminault, 1994). Lastly, impotence or lack of sex drive
has been noted in approximately 28% of patients with OSAS (Guilleminault, 1994).
Certain medical conditions are associated with OSAS, and certain drugs can
influence the severity o f OSAS. Obesity (i.e., being 20% or more above ideal body
weight) is present in approximately two thirds o f patients with OSAS (Guilleminault,
1994). Additionally, cardiovascular disease and arterial hypertension are clearly
associated with OSAS (Shepard, 1994). CNS depressant drugs can exacerbate the
severity of OSAS, and alcohol ingested close to bedtime has been shown to increase the
number of complete obstructive apnea events and to prolong their duration (Issa &
Sullivan, 1982; Scrima, Broudy, Nay, & Cohn, 1982). This phenomenon holds true for
hypnotics and tranquilizers if taken close to bedtime because they have effects similar
to alcohol (Sanders, 1994).
Assessment o f OSAS
Approximately 74,600 patients undergo polysomnography in accredited sleep
disorders centers each year, and about 75% of these patients are diagnosed with OSAS
(American Thoracic Society [ATS], 1994). Although presenting complaints o f loud
5
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snoring and EDS may suggest the presence of OSAS, a diagnosis can only be made
after the patient's sleep is studied objectively by physiological means, which is usually
conducted in a sleep laboratory. A nocturnal diagnostic polysomnography (PSG), or
sleep study, is the best clinical method for diagnosing the presence of OSAS.
Polysomnographic assessment o f OSAS should include central and occipital measures
of electroencephalogram (EEG), electrooculogram, electromyogram (EMG), nasal/oral
airflow, respiratory muscle effort, electrocardiogram, and blood oxygen saturation
(pulse oxygen; ATS, 1994). The physiological recording of respiration during an
episode of sleep apnea reveals that airflow ceases or is greatly reduced periodically,
which is evident at the level o f the nostrils and mouth, while strain gauges
encompassing the patient’s chest and abdomen register the continuous respiratory effort
of the diaphragm and intercostal muscles. Transient arousals resulting from respiratory
events (apneas or hypopneas) are apparent in the EEG and EMG channels as bursts of
phasic activity that are easily discernible from baseline. A multiple sleep latency test
(MSLT) can be used to determine the extent of excessive daytime sleepiness, though
this is not essential for diagnostic assessment. The MSLT is an objective measure of
daytime sleepiness and consists of a series of four or more nap opportunities, which are
scheduled for every two hours beginning two hours after a night of sleep in the
laboratory (Carskadon & Dement, 1977). The measure of daytime sleepiness for the
MSLT is the sleep onset latency, with values five minutes or less indicating
pathological sleepiness.
Pathophysiology and Mechanics o f Upper Airway Resistance
Resistance o f airflow during sleep exists on a continuum from that which is
detectable only with special diagnostic equipment, to mild snoring, to a range o f severe

6
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blockages o f the pharynx as occurs during SAHS (Guilleminault, 1994). Factors such
as the decreased upper airway patency, that is hypothesized to stem from changes in
neuromuscular control brought about by sleep (e.g., hypotonicity), and various
anatomical abnormalities o f the structures surrounding the airway (e.g., excess fatty
tissue, stenosis of the upper airway, maxillofacial abnormalities) result in increased
resistance o f airflow in the upper airway (Isono & Remmers, 1994). Moreover,
resistance o f airflow in the upper airway during wake has been found to be greater in
patients with OSAS than in control subjects (Anch, Remmers, & Bunce, 1982).
Although the upper airway consists of the extrathoracic trachea, the larynx, the
pharynx, and the nose, the pharynx is the only segment of the respiratory tract that is
capable of collapsing during sleep apnea (Isono & Remmers, 1994). The pharynx is a
specialized portion o f the upper airway and has additional functions other than
conducting gases to and from the lungs. This structure is involved in swallowing and
phonation, and by necessity is a highly flexible structure under sophisticated CNS
control (Isono & Remmers, 1994). During wakefulness, pharyngeal patency is
maintained by continual neuromuscular control of the CNS and by a balance o f internal
and external airway pressures. In the absence of full neuromuscular control o f the
upper airway, such as occurs in sleep (especially REM sleep), the pharyngeal lumen
(the total cross-sectional area that gases may pass through) of the passive pharynx is
influenced to a greater degree by the balance of internal and external pressures sources.
The tube law for the passive pharynx model states that the size of the pharyngeal lumen
is determined by opposing pressure forces located within and external to the upper
airway (Isono & Remmers, 1994). The absolute effect of these forces on the size of the
pharyngeal lumen in the absence of muscular activity is referred to as the transmural
7
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pressure of the passive pharynx and is determined by a balance of luminal pressure (i.e.,
outward lateral pressure acting on the internal pharyngeal wall) and tissue pressure
compressing the external wall o f the pharynx, which comes form a variety of sources
(e.g., large tongue, gravity acting on excess submandibular fat; Isono & Remmers,
1994). The air pressure inside the pharynx differs from atmospheric pressure during
airflow and is influenced by the acceleration of flowing gas. This acceleration of gas
increases kinetic energy in the narrowed upper airway, and diminishes potential energy
(i.e., luminal pressure) in the section of the pharynx below.
Two factors responsible for occlusion of the airway during an apnea are
inspiratory flow limitation and closing pressure. Inspiratory flow limitation is the
concept that maximal inspiratory flow through the pharynx to the lungs remains
relatively constant despite the progressive narrowing of the pharynx and increased
resistance to the gas flow. Thus, as resistance against the gas flow increases, more
potential energy is lost in overcoming the friction, thus resulting in a loss of luminal
pressure and a further reduction of airway patency. Finally, the loss of lateral wall
pressure reaches a critical value (i.e., closing pressure) that results in the absence of the
pharyngeal lumen (Isono & Remmers, 1994).
In contrast to the passive phase, the active phase of the pharyngeal lumen is
stated to occur when muscles that determine the luminal air space are in a state of
contraction, and the airway is dilated. A phasic burst of reflexual muscle contraction
that dilates the upper airway opposes the collapsing negative pressure produced by the
rapid airflow o f inspiration (Harper & Sauerland, 1978). The action of upper airway
musculature interacts with sources o f internal and external pressure, and these muscles
are active during wake and sleep. However, for reasons yet to be completely
8
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understood, neuromuscular control of the upper airway is decreased during sleep, and it
is hypothesized that changes in neuromuscular input interacts with a variety of factors
including neck flexion, positioning of the jaw, and anatomical abnormalities of the
upper airway, all of which influence airflow through the pharynx (Isono & Remmers,
1994). For example, when the mouth opens during sleep, the length o f the genioglossus
and geniohyoid muscles decreases, thus diminishing the effect of efferent neural activity
(Isono & Remmers, 1994). Consequently, the ability of muscles which dilate the
pharyngeal lumen to compensate for losses of transmural pressure is impaired during
sleep by a variety of factors, any of which can contribute to the pathogenesis of OSAS
(Isono & Remmers, 1994).
Structural Abnormalities of the Upper Airway in Patients with OSAS
As stated previously, the upper airway is the final common anatomical location
for changes in respiratory control and neuromuscular functioning that lead to sleep
apnea (Pepin, Levy, Veale, & Ferretti, 1992). Various techniques have been used to
examine the upper airway, and OSAS patient samples have been examined during
waking and sleep. Lateral radiography cephalometry has revealed that the vast majority
o f patients with OSAS have abnormalities on cephalometric roentgenograms (Pepin et
al., 1992). In a study of 155 patients with OSAS, 150 had at least two abnormalities of
the upper airway (Jamieson, Guilleminault, Partinen, & Quera-Salva, 1986). Patients
with OSAS have been found to have a longer and thicker soft palate as compared to
normal subjects (De Berry-Borowiecki, Kukwa, Blanks, & Irvine, 1988; Lyberg,
Krogstad, & Djupesland, 1989). A reduction in the size o f the posterior airway space
below 5 mm (normal = 11mm + 1mm) and a value of greater than 24 mm (normal =
15.4 mm ± 3mm) for the distance from the mandibular plane to the hyoid bone (anchors
9
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the tongue muscles) has been found to correlate with the A+HI independent of the body
mass index (BMI; Partinen, Guilleminault, Quera-Salva, & Jamieson, 1988).
Additionally, cephalometric studies have revealed that the hyoid bone tends to be
abnormally low in persons with OSAS (De Berry-Borowiecki, et al., 1988).
Computerized tomography (CT) of the upper airway in a sample o f OSAS patients has
shown that the cross section area of each level of the pharynx is significantly reduced as
compared to normal control subjects (Haponik, et al., 1983). The use of CT has shown
increased tongue volume in patients with OSAS (Lowe, Gionhaku, Takeuchi, &
Fleetcham, 1986). Using ultrafast CT instead of conventional CT techniques, Shepard,
Stanson, Sheedy, and Westbrook (1990) found that the most significant narrowing of
the upper airway in OSAS patients during waking occurred at the end o f expiration at
the level of the oropharyngeal segment. A study o f sleeping OSAS patients, found that
collapse of the upper airway occurred at pressures ranging from - 0.5 to -8.9 cm H20
(Issa & Sullivan, 1984). Airflow may be altered at various points in the upper airway,
and such anatomical defects have a deleterious influence on the airflow mechanics.
Determinants of Daytime Sleepiness and Impaired Functioning in OSAS
Transient arousals from sleep detectable in the EEG as bursts o f alpha waves
and K-complexes reflect changes in CNS activity. Transient arousals from sleep often
occur with the termination of sleep apneas and hypopneas and indicate that an
activation of bodily defense mechanisms has occurred in response to a cessation of
breathing. However, changes in the EEG associated with the termination of sleeprelated respiratory events are not the only alterations in physiological variables that
occur in OSAS. A pattern o f sympathetic nervous system (SNS) responses generally
occurs at the conclusion of an apnea, with increased heart rate being the cardinal feature

10
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(Guilleminault, 1982). Additionally, it is not uncommon for increases in heart rate to
reach the point o f tachycardia (i.e., over 100 beats per minute in adults; Guilleminault,
1982). Other components o f SNS response include increased heart volume, constriction
of blood vessels, and deeper and faster respiration (Guilleminault, 1994). At the
conclusion of an apnea, respiration is resumed by homeostatic CNS respiratory
mechanisms, which maintain blood gases in a range so that the metabolic functions of
the body remain normal (Douglas, 1994). Evidence suggests that the hypercapnic
ventilatory response to increasing levels of carbon dioxide plays a significant role in
arousal from sleep during respiratory changes in OSAS, although hypoxemia, the level
of ventilatory effort, and increased inspiratory resistance in the upper airway all make
contributions to the respiratory arousal response that resumes breathing (Douglas,
1994). It is arguable that the arousal from sleep which occurs in response to increasing
levels of carbon dioxide in OSAS is the most vital defense mechanism in response to
breathing abnormalities during sleep, and commonly, arousals to the point of awakening
are an important contributor to the decision to seek treatment (Guilleminault, 1982).
The severe sleep disruption experienced by persons with OSAS alters the sleep
architecture and diminishes the restorative quality o f sleep (Roth, Hartse, Zorick, &
Conway, 1980). Sleep fragmentation in the form of numerous, brief arousals from sleep
has been demonstrated to be a significant contributor to EDS in the elderly and in
persons with certain sleep disorders such as OSAS and periodic limb movement
disorder (Carskadon, Brown, & Dement, 1982; Walsh & Lindblom, 1997). Sleep
fragmentation is typically manifested by discrete intrusions of alpha wave activity in the
sleep EEG, which are referred to clinically as transient arousals from sleep. Transient
arousals from sleep often coincide with the termination of apneas and by definition last
11

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

from 3 to 14 seconds (ASDA, 1992). In cases of severe OSAS, persons may experience
hundreds of these transient EEG changes per night (Guilleminault, 1994). The effect of
such severe sleep fragmentation is that the sleep quality of persons with OSAS may be
so poor that it approximates total sleep deprivation. Daytime nap studies of patients
with OSAS have shown significantly reduced sleep onset latencies compared to those of
normal sleepers, with OSAS patients typically falling asleep within 2 to 3 minutes on
average during trials of the MSLT (Roth et al., 1982).
Additional evidence for the increased daytime sleepiness which results from
sleep fragmentation comes from experimental studies in normal sleepers where
approximations of the sleep disruption experienced by persons with OSAS has been
shown to significantly reduce sleep onset latencies for the MSLT (Bonnet, 1985, 1986,
1987; MaGee, Harsh, & Badia, 1987; Philip, Stoohs, & Guilleminault, 1994; Roehrs,
Merlotti, Petrucelli, Stepanski, & Roth, 1994). Complete awakenings after each minute
of sleep in normal subjects have been shown to result in sleep onset latencies during
MSLT trials similar to those observed after 64 hours of total sleep loss, even after
controlling for the total sleep time (Bonnet, 1986). Changes in the sleep architecture
during recovery sleep in persons who have undergone experimental sleep fragmentation
are identical to those found in persons who have undergone total sleep deprivation, with
rebounds of stages 3 and 4 NREM sleep and REM sleep being observed (Downey &
Bonnet, 1987). Additionally, transient EEG arousals occurring as infrequently as once
every four minutes during sleep have been shown to result in significantly reduced sleep
onset latencies for the MSLT, even when the total sleep time approximated that of the
baseline polysomnography (Roehrs et al., 1994). Other forms of sleep disruption
including shifts to a lighter stage o f sleep have been shown to contribute significantly to
12
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sleepiness as measured by the MSLT (Stepanski, Lamphere, Badia, Zorick, & Roth,
1984). Roth et al. (1980) found that a measure of sleep disruption, which they referred
to as arousals subsequent to respiration (which included increases in submental EMG
activity and leg movements accompanying respiratory-related arousals), was
significantly correlated (r = -0.67) with daytime hypersomnolence as measured by the
MSLT
There is strong evidence to suggest that the EDS resulting from sleep
fragmentation is the primary cause of impaired performance in persons with OSAS.
Bonnet (198S, 1986, 1987) has demonstrated that sleep fragmentation has detrimental
effects on daytime cognitive functioning. Subjects who were awakened after each
minute of unambiguous sleep (a brief verbal response was required to confirm an
awakening) performed significantly worse on a simple reaction time task, completed
significantly fewer addition problems correctly in the Wilkinson Addition Task, and
performed significantly worse on a symbol substitution task as compared to baseline
(Bonnet, 198S). Similar results were obtained in a subsequent experiment where
disruptions after each minute o f sleep resulted in fewer correct addition problems and
performance lapses for a vigilance task (Bonnet, 1986). Hit rates for a vigilance task
were significantly impaired in healthy subjects across three levels o f sleep disruption on
the morning following two consecutive nights of experimental sleep fragmentation
(Bonnet, 1987). Lapses in vigilance can often be attributed to repeated microsleeps,
during which persons who have experienced significant sleep deprivation involuntarily
fall asleep briefly during boring or repetitive tasks (Aldrich, 1994). Furthermore, after
36 consecutive hours of sleep deprivation, the skin conductance orienting response to
auditory stimuli, which reflects attentional shifts and allocations o f attentional
13
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resources, has been shown to have significantly increased response latency, decreased
response amplitude, and faster response habituation which was clearly attributable to
sleep loss (McCarthy & Waters, 1997). Thus, physiological changes in the mechanisms
underlying attention may also be caused by sleep deprivation and may contribute
importantly to impaired performance in patients with OSAS.
Blood gas disturbance in the form of intermittent hypoxemia due to sleep apnea
has been shown to be a significant contributor to impaired neuropsychological test
performance in persons with OSAS (Bedard, Montplaisir, Malo, Richer, & Rouleau,
1993; Bedard, Montplaisir, Richer, & Malo, 1991; Greenberg, Watson, & Deptula,
1987). Additionally, evidence o f memory and spatial skills impairments have been
shown to occur in heavy snorers without OSAS, with performance decrements being
significantly correlated with the number of oxygen desaturations greater than 4% during
sleep (Telakivi et al., 1988). Greenberg et al. (1987) found that OSAS patients
performed significantly worse than control subjects on 7 of 14 neuropsychological
measures and on a global rating of impairment. Impairments of motor and perceptualorganizational abilities in patients with OSAS were significantly correlated with total
time not breathing (i.e., number of apneas multiplied by mean duration) and the lowest
blood oxygen desaturation. However, the global rating of impairment was not
significantly correlated with either of these measures, but instead was correlated with an
estimate o f illness duration (Greenberg et al., 1987). Nocturnal hypoxemia from OSAS
has also been shown to be an important contributor to impaired executive functioning
and vigilance (Bedard et al, 1993; Bedard et al, 1991). The minimum Sa02 value
during sleep was shown to be significantly correlated (r = -0.76) with increased reaction
time on a vigilance task (Bedard et al, 1991). Although treatment with CPAP over a 6
14
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to 10 month period improved the sleep architecture, respiration during sleep, vigilance,
and problems with memory impairment, chronic use o f CPAP did not reverse deficits
for executive and psychomotor functioning (Bedard et al, 1993). The authors concluded
that persistent deficits observed in persons receiving CPAP treatment for moderate to
severe OSAS were most likely the result o f the severity of nocturnal hypoxemia. It
remains to be seen, however, whether nocturnal hypoxemia causes poor quality sleep
that impairs functions such as attentional orienting or affects performance via
microsleeps.
CPAP Therapy for the Treatment of OSAS
Nasal CPAP was first described as a treatment of OSAS in 1981 (Sullivan,
Berthon-Jones, Issa, & Eves, 1981), but was not widely recognized as an acceptable
therapy for OSAS until 1985 (Sullivan & Grunstein, 1994). The most important effect
of CPAP on the upper airway is that it acts as an air-pressure splint, which maintains the
patency o f the upper airway by providing continuous pressure to the interior o f the
airway that prevents it from collapsing (Sullivan & Grunstein, 1994). According to
members of the ATS (1994), nasal CPAP is the most effective treatment of OSAS.
Nasal CPAP has been demonstrated to be superior to other major modes o f treatment
for OSAS. In a randomized, controlled trial comparing treatments for OSAS, Lojander
et al. (1996) demonstrated CPAP to be superior to palatal surgery and to a conservative
management condition (a minimal treatment control condition). In a randomized,
crossover study comparing CPAP and an oral appliance (an acrylic polymer
mouthpiece) for the treatment of OSAS, CPAP produced no treatment failures as
compared to a failure rate of 28% for the oral appliance (Ferguson, Ono, Lowe, Keenan,
& Fleetham, 1996).
15
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CPAP uses a facial mask, or some other means o f interface (such as intra-nasal
tubes) with the upper airway, connected to an air pump that generates pressure in the
airway while also allowing the ventilation of expired carbon dioxide. Important
therapeutic supplements that can be used with CPAP are oxygen for patients whose
Sa02 levels do not normalize and humidification to make use more comfortable by
reducing the tendency for CPAP to cause nasal dryness. The most common method of
air pressure delivery is with a nasal mask, which is manufactured in standard sizes,
although some companies offer custom fitting for patients with unusual facial contours.
Generally, the construction of the nasal masks consists o f an outer shell o f hard plastic
with a soft inner seal constructed of rubber or rubber filled with silicone gel. One major
variation o f CPAP pressure delivery is nasal prongs, which enter the nostril and form a
seal around the opening o f the nostril.
The first pressure generating devices for CPAP treatment were air compressors,
which although effective, were considered by patients to be bulky and noisy. An
advance in the CPAP delivery technology came with the replacement of air compressors
with air blowers. Advantages of air blowers include smaller size, greatly reduced noise
(they are more easily insulated), and their ability to compensate for a loss o f mask
pressure due to an imperfect seal with the face (Sanders & Kern, 1992). Currently
manufactured CPAP devices are designed to deliver pressures from 2 to 20 cm H20,
and pressures up to 10 to 12 cm H 20 are usually well tolerated (Sullivan & Grunstein,
1994). Because inhalation and exhalation are conducted through the nasal mask, it is
necessary to provide a means for the removal of expired C02. Common ways of
dealing with this problem are to place a small hole in the mask, or to attach a special
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valve to the mask, which serves to deflect expiratory flow out of the system. These
devices produce an air leak o f approximately 10 to IS L/min (ATS, 1994).
There are some variations in the pressure delivery of CPAP blower systems.
Patients often find exhalation more difficult than inhalation on CPAP because they must
exhale against the airflow. The first method of modified pressure delivery designed to
address this problem was bi-level positive airway pressure (i.e., BiPAP), which was
developed by the Respironics Corporation. The BiPAP system allows the inspiratory
and expiratory air pressure levels to be adjusted independently, and was designed to
make the positive airway pressure more tolerable. This means of pressure delivery
allows for a higher pressure level to be set for inspiration (inspiratory positive airway
pressure), without equivalent high pressure for expiration (expiratory positive airway
pressure level) and the greater discomfort that this might cause. However, the
expiratory positive airway pressure level is essential for treatment efficacy and must be
equivalent to the effective pressure level o f CPAP, which still requires patients to
exhale against the same pressure as would be used with CPAP.
The newest variation on pressure delivery is automatic CPAP, which delivers
varying amounts of pressure throughout the night according to the amount required to
eliminate snoring and sleep apnea in any given sleep stage and sleep position. A
specific range o f CPAP pressures is set for the automatic CPAP device, with the lowest
pressure being utilized at the beginning of any sleep period. The major theoretical
advantage of automatic CPAP is increased patient comfort, because only the amount of
pressure that is needed at any given point in the sleep period is delivered. For example,
higher pressures are generally required during REM sleep, because of increased
irregularity o f breathing and atonia, and when persons are sleeping in the supine
17
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position due to the increased collapsibility of the airway specific to this position
(Sullivan & Grunstein, 1994). Higher CPAP pressures levels are usually required after
the ingestion o f even moderate amounts of alcohol or any other muscle relaxant
(Sullivan & Grunstein, 1994). The ingestion of alcohol has been shown to increase the
number sleep apneas and hypopneas and result in a significant increase in the number of
episodes o f oxygen desaturation in a sample o f men without symptoms of OSAS
(Taasan et al., 1981). Alcohol ingestion also has been shown to exacerbate the severity
of OSAS (Issa & Sullivan, 1982; Scrima et al., 1982).
There are very few contraindications for the use of nasal CPAP for the treatment
of OSAS. Nasal CPAP should not be used with patients who have sustained traumatic
head or spinal injury that has caused leakage o f cerebrospinal fluid, but otherwise, there
are no major contraindications (Sullivan & Grunstein, 1994). When CPAP use is
feasible for OSAS, the amount of nasal airway pressure used should restore adequate
ventilation and blood oxygenation, and should reduce transient arousals from sleep so
that sleep is more continuous and the sleep architecture is normalized (ATS, 1994). The
CPAP pressure level is usually titrated in the sleep laboratory setting. Currently, there
is no standardized procedure for CPAP titration, but the following are regarded as the
primary objectives during a CPAP titration: (1) restoration of a normal respiration
pattern; (2) restoration o f normal blood oxygen level; (3) normalization of the sleep
architecture; (4) elimination of airway resistance (particularly snoring), and; (S)
reduction o f breathing-related associated transient arousals from sleep to normal levels
(ATS, 1994). A range o f CPAP pressures is used during the titration procedure with the
primary goal being to find a pressure level that is sufficient to prevent apnea, hypopnea,
and snoring in all stages o f sleep and in all postures o f sleep (ATS, 1994; Sullivan &
18
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Grunstein, 1994). Great care must be taken to examine treatment efficacy under these
varying conditions because the supine sleep position will require a higher pressure than
a lateral or prone sleep position, and REM sleep will require higher CPAP pressures
(Sullivan & Grunstein, 1994).
Regular use o f CPAP by those with OSAS has been shown to alleviate daytime
sleepiness (Frith & Cant, 198S; Kribbs et al., 1993a; Rajagopal, Bennett, Dillard, Tellis,
& Tenholder, 1986) and to reduce waking C 02 levels (Berthon-Jones & Sullivan,
1987).

Improvements in cardiovascular functioning such as acute reduction of

elevated nocturnal blood pressure levels in OSAS patients with hypertension has been
demonstrated with the regular use of CPAP (Fletcher, 1996). Furthermore, chronic
application of CPAP for the treatment of OSAS has also been shown to result in a
reduction of waking blood pressure levels in OSAS patients (Fletcher, 1996).
Additionally, chronic use of CPAP has been shown to be associated with increased
waking upper airway dimensions (Ryan, Lowe, Li, & Fleetham, 1991). Long-term
assessment of daytime sleepiness with the MSLT has shown continuous improvement
of daytime sleepiness in OSAS patients treated with CPAP that was not always evident
at the beginning of treatment, with MSLT values continuing to normalize after the first
50 days of treatment (Meurice et al., 1997). Symptoms return quickly when CPAP is
discontinued, and only one night’s sleep without CPAP has been shown to result in a
return to pre-treatment levels of sleepiness and psychomotor vigilance (Kribbs et al.,
1993a).
Changes in the Sleep Architecture from CPAP Treatment
The sleep architecture of those suffering from OSAS is significantly different
from that of normal sleepers, with OSAS patients spending reduced amounts o f time in
19
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SWS and REM sleep and spending increased amounts of time in stage 1 NREM (Roth
et al., 1980). The deficit observed for SWS is a clinically significant finding because
stages 3 and 4 NREM sleep are particularly restorative (Roth et al., 1980). If a proper
level o f CPAP pressure is titrated in OSAS patients, there is generally a large rebound
of slow wave sleep followed by a similarly large rebound o f REM sleep. These
rebound phenomena are most dramatic during the first night o f CPAP, but rebound of
these sleep stages is apparent for about one week after the initiation o f treatment
(Sullivan & Grunstein, 1994). Regular and proper use of CPAP treatment for OSAS
restores the sleep architecture and reduces rates of transient arousals from sleep and
awakenings to within normal ranges, provided there is not another comorbid sleep
disorder (Isono & Remmers, 1994). For example, Pieters et al. (1996) showed that
CPAP treatment in patients with OSAS significantly increased the percentage of stages
3 and 4 NREM sleep, REM sleep, and decreased the number o f arousals per hour asleep
as compared to baseline.
Surgical Treatment for OSAS
Tracheostomy is an effective surgical intervention for the treatment of OSAS,
but is disfiguring and can have serious complications as it is highly prone to
opportunistic infections. Uvulopalatopharyngoplasty (UPPP) is a surgical intervention
for OSAS in which the uvula and a large portion o f the soft palate are excised, and is a
better surgical alternative than tracheostomy (Rodenstein, 1992). Surgery is usually
performed under general anesthesia and the operation consists of resection of roughly
1.5 cm o f the free palate, followed by suturing the posterior and anterior tonsillar pillars
together. The anterior and posterior edges of the remaining palate are sutured together
to complete the operation. In examinations o f the efficacy o f UPPP, many investigators
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have arbitrarily defined treatment responders as patients who exhibit a reduction of the
A+HI by more than 50% from baseline. However, only a minority of patients are
classified as UPPP responders and complete elimination of OSAS is rare (Rodenstein,
1992). Several studies have reported success rates o f less than 50% (Simmons,
Guilleminault, & Miles, 1984; De Berry Borowiecki, Kukwa, & Blanks, 1985).
Disregarding treatment responder status, De Berry Borowiecki et al. (1985) reported
that 60% o f patients had an apnea index o f > 20 after UPPP surgery. This is an
important result because significantly increased mortality has been noted in patients
with an apnea index o f >20 per hour (He, Kryger, Zorick, Conway, & Roth, 1988).
Complications most commonly occurring after UPPP are transient nasopharyngeal
regurgitation, rhinolalia, and infections (Rodenstein, 1992). Mortality may be indirectly
increased in patients undergoing UPPP as compared to patients treated with
tracheostomy or CPAP. In a 5-year to 8-year follow-up study of patients treated by
either UPPP, CPAP, or tracheostomy, all of the patients who died (w = 14) were treated
by UPPP (He et al., 1988).
Laser-assisted uvulopalatoplasty (LAUP) has been promoted as a safer surgical
alternative than the UPPP for the treatment of OSAS (Walker, Grigg-Damberger, &
Gopalsami, 1999). Furthermore, research suggests that treatment outcomes from the
LAUP procedure are comparable to those obtained with UPPP in terms o f reduced
A+HI (Mickelson, 1996; Pribitkin et al., 1998). Although the LAUP procedure has
been shown to be effective in the treatment of snoring, it has not been shown to be
particularly effective in reducing the RDI of OSAS patients, and might only be a viable
treatment option for patients with milder illness (Pribitkin et al., 1998).
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Non-surgical Treatments for OSAS other than CPAP
Tongue-retaining devices have been tested in large numbers of patients (Lowe,
1994). These devices consist of custom-made mouthpieces that are designed to
maintain the patency o f the pharynx by creating suction on the tongue and extending it
past the teeth. The devices are bulky and tolerance of their use is 50% at best (Lowe,
1994). Additionally, patients must be able to breathe freely through the nose, which
may be impossible given the anatomical abnormalities commonly found in patients with
OSAS. These devices are generally only effective with patients whose OSAS is
ameliorated by sleeping on the side and treatment generally leads to improvement rather
than elimination o f air resistance (Cartwright & Samelson, 1982). Although weight loss
would seem to be a logical recommendation for patients with OSAS, weight loss is
rarely ever achieved on a permanent basis and regular use of CPAP is arguably a less
demanding and more achievable treatment regimen for OSAS than the maintenance of
significant weight loss (Smith, Gold, Meyers, Haponik, & Bleecker, 1985). Finally,
positional conditioning can be effective for persons who experience apnea only in the
supine sleeping position (Cartwright, 1984; George, Millar, & Kryger, 1988). In this
procedure, the patient is trained to avoid sleeping in the supine position, which can be
accomplished by wearing a device (e.g., a pajama shirt with a ball sewn into the back)
that makes sleeping on the back aversive.
CPAP Compliance
In general CPAP compliance is less than optimal and may even be less than
adequate (Kribbs, 1997). Currently, no broadly accepted definition of CPAP
compliance in OSAS patients has been formulated, and CPAP compliance has been
defined variably across studies (Collard, Pieters, Aubert, Delguste, & Rodenstein,
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1997). In general, CPAP compliance has referred to the degree to which patients who
accept this form of treatment for OSAS actually use it (Collard et al., 1997). A sample
of the various definitions of CPAP compliance that can be found in published research
include: self-report estimates of persistent daily use without objective verification of
actual time used (Rolfe, Olson, & Saunders, 1991); persistent (although not necessarily
daily) use o f CPAP at the time of follow-up (Waldhom et al., 1990; Hoffstein, Viner,
Mateika, & Conway, 1992); the average number of hours of daily use as measured from
built-in use clocks (Pieters et al., 1996; Fletcher & Luckett, 1991); more than 3 hours
per night o f daily use (Krieger & Kurtz, 1988); at least 4 hours of use on 70% of the
nights measured (Kribbs et al., 1993b); at least 4 hours of use per night on average
(Rauscher, Formanek, Popp, & Zwick, 1993); and daily use averaging at least 5 hours
per night (Meurice et al., 1994). For persons who use CPAP on nearly a daily basis,
compliance has been found to range on average from 5 to 6.5 hours per night (Collard et
al., 1997; Krieger & Kurtz, 1988; Fletcher & Luckett, 1991; Engleman et al., 1996).
However, most studies using objective means o f measuring CPAP use as measured by
clocks which record the total time CPAP is on have generally found use averaging less
than five hours per night (Berthon-Jones, Lawrence, Sullivan, & Grunstein, 1996;
Engleman, Martin, & Douglas, 1994; Rauscher et al., 1993; Reeves-Hoche, Meek, &
Zwillich, 1994). Additionally, a close examination of patterns of CPAP use suggests
that there can be considerable night-to-night variability o f use even in patients
considered to be compliant (Kribbs et al., 1993b; Rauscher et al., 1993). For example, a
study by Kribbs et al. (1993b) found that only 2 of 35 (6%) patients used CPAP for 7
hours or more per night every night. Furthermore, Rauscher et al. (1993) discovered that
only 30% o f a sample o f patients used CPAP for more than 80% o f their reported time
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in bed. It is also apparent that patients may take frequent self-prescribed breaks from
treatment during situations such as illness, travel, weekends, or may use CPAP on
alternate nights or for only part of the night (Rauscher et al, 1993).
The earliest phase o f CPAP compliance has been referred to as acceptance
(Collard et al., 1997). A considerable barrier to implementing CPAP therapy for OSAS
is that many patients refuse CPAP as a treatment option initially or following a fullnight or split-night CPAP titration trial in the laboratory (Waldhom et al., 1990).
Rauscher et al. (1993) found that 32% of patients refused a CPAP titration trial from the
outset, and 28% o f the remaining sample o f patients who agreed to undergo a titration
trial elected not to use CPAP for treatment of their OSAS. Thus, 49% of the original
sample (N = 95) refused regular home CPAP treatment for OSAS either initially as a
treatment option or after undergoing one night of CPAP titration in the laboratory
(Rauscher et aL, 1993). Pieters et al. (1996) obtained similar results in a sample of
patients with OSAS and found that 24% of patients refused CPAP as a treatment option
after a night of titration in the laboratory.
After the initial acceptance of CPAP for home treatment of OSAS, attrition rates
are high. In a retrospective study of 168 patients prescribed CPAP therapy, only 64%
o f patients continued to use CPAP at the time of follow-up (ranged from 1.5 months to
78 months, Rolfe et al., 1991). Similar results for attrition have been obtained in other
follow-up studies, with rates of compliance ranging from 65 to 68% (Nino-Murcia,
McCann, Bliwise, Guilleminault, & Dement, 1989; Meurice et al., 1994). Although
various follow-up intervals have been used within and between studies in attempts to
ascertain compliance rates for CPAP, it appears that the first few weeks or, at most, the
first few months after CPAP therapy is initiated are critical in promoting long-term
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compliance (Nino-Murcia et al., 1989; Collard et al., 1997). Most patients who
discontinue CPAP will do so shortly after beginning treatment, and use of CPAP during
the first month has been shown to strongly predict use at 3 months (Kribbs et al., 1993b;
Fleury, Rakotonanahary, Tehindrazanarivelo, Hausser-Hauw, & Lebeau, 1994).
Hoffstein et al. (1992) found that patients who quit CPAP therapy returned their
equipment after an average o f 3 months. Rolfe et al. (1991) found similar rates for
discontinuation of CPAP with 78% of noncompliant patients stopping treatment within
two months and 90% by four months. Conversely, for those who continue to use CPAP
after the first few months, compliance has been shown to be very stable, with compliant
patients continuing to use CPAP for an average o f five hours per day over two
consecutive follow-up periods covering a total of three years (Pieters et al., 1996).
Methods of Measuring CPAP Compliance
The ATS (1994) recommends routine follow-up to evaluate a patient’s response
to CPAP therapy, which should include some objective measurement of compliance. In
the CPAP treatment literature, methods of measuring compliance have included
subjective self-report of daily use and objective methods o f measurement including total
machine run time, monitored with built-in time clocks, and/or measurement of effective
application o f CPAP and patterns of use via microchips, which can record the exact
amount of time that CPAP is at or near the prescribed pressure (Collard et al., 1997).
Microchip technology also allows precise analysis o f patterns of use with date and time
of each instance that the machine is switched on and off (Collard et al., 1997). Early
studies of CPAP compliance in OSAS patients yielded favorable results; however, these
investigators did not utilize objective means to verify actual patient compliance with
CPAP, with self-report used as the primary measure (e.g., Sanders, Gruendl, & Rogers,
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1986). Furthermore, comparisons of patients’ estimates and objective measures of
compliance reliably show that patients overestimate their average use of CPAP by
approximately one hour per night (Rauscher et al., 1993, Kribbs et al., 1993b). The
introduction of objective measures o f CPAP use has allowed more accurate assessment
of compliance. For example, using microchip technology capable o f recording machine
time on and time off, and the total time at the prescribed pressure for each day, Kribbs
et al. (1993a) found that there was often a large variation of use across days for many
patients.
Internal clocks by themselves may be adequate for the assessment of CPAP
compliance, as consistent and only slight differences between machine time on and time
at effective pressure have been found across studies; moreover, there is a very high
correlation between these two CPAP use measures, generally on the order of r = .90
(Collard et al., 1997). These findings have brought many investigators to the conclusion
that monitoring compliance with an internal clock that records total hours of use is
necessary and sufficient (Pieters et al., 1996). However, it has been argued that the use
o f this technique does not allow for an examination of patterns o f use, because only the
average daily use time is available as opposed to the more detailed night-by-night use
data achievable via computer microchip technology (Kribbs, 1997).
Predicting CPAP Compliance
There have been several investigations that have attempted to identify which
patient or sleep variables might predict the degree of CPAP compliance. However, no
consistent predictive factors have emerged, and statistically significant relations
between the variables examined and the criterion of compliance have been shown to be
generally weak (Collard et al., 1997). One prospective study of 47 patients with OSAS,
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which measured CPAP use covertly with an electronic recording device, found no
significant predictors of compliance (Reeves-Hoche et al., 1994). Data analyzed in this
investigation included pre-treatment A+HI, age, gender, BMI, education level,
prescribed CPAP pressure, and subjective daytime sleepiness (Reeves-Hoche et al.,
1994). Employing a similar group o f predictor variables, Fletcher and Luckett (1991)
also did not find any significant predictors of hourly compliance, although it should be
noted that the sample of OSAS patients was very small (N= 10). Moreover, initial
severity of sleep apnea, effectiveness o f CPAP in normalizing the sleep architecture,
blood oxygen levels, reported side effects, and prescribed CPAP pressure level were not
shown to discriminate between compliant and noncompliant patients (Waldhom et al.,
1990).
In contrast, other studies have found significant relationships between
polysomnographic/patient predictor variables and the criterion variables of acceptance
and average nightly use o f CPAP treatment. Significant correlations have been
observed between the average nightly use o f CPAP and the polysomnographic
parameters of pre-treatment A+HI
(r = .37), the combined percentage of stage 1 and stage 2 NREM sleep (r = 30), and the
combined percentage stage 3 and stage 4 NREM (r = -.31) sleep during the diagnostic
PSG (Meurice et al., 1994). Additionally, Meurice et al. (1994) found significant
correlations between nightly use of CPAP and the degree of improvement from baseline
to post-treatment for the A+HI (r = -.34) and mean Sa02 during sleep (r = .38). Studies
of CPAP compliance by Hui et al. (2001) and Bennett, Langford, Stradling, and Davies
(1998) have also found significant correlations between the pre-treatment A+HI and
CPAP use with correlations o f r = .21 and rs= .34 being observed respectively Also,
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objective CPAP use has been found to significantly correlate with lowest Sa02 during
the baseline study (r = -.26; Rauscher et al., 1993). In a study o f 168 patients prescribed
CPAP, significantly more patients with both EDS and Sa02 desaturation below 75%
were using CPAP at follow-up (Rolfe et al., 1991). However, it should be noted that
this sample included a large number o f patients who did not have OSAS and were being
treated with CPAP for snoring, and the study did not use objective means of measuring
compliance. A significant difference has been observed between patients with milder
and more severe OSAS in initial acceptance o f CPAP, with only 28% o f mild to severe
OSAS patients (A+HI between 15 and 30) accepting CPAP therapy versus 95% of those
with very severe OSAS (A+HI > 60; Rauscher, Popp, Wanke, & Zwick, 1991b).
Hoffstein et al. (1992) found that compliant CPAP users had a significantly higher mean
BMI than non-compliant patients. Finally, full-night titration studies are often used to
set an effective level o f CPAP pressure, but, as a cost saving measure, many sleep
disorders centers routinely conduct a 2 to 4 hour baseline and begin CPAP titration for
the remainder of the night (i.e., split night studies) if warranted and/or feasible. Fleury
et al. (1994) found that acceptance and compliance rates for CPAP in patients who were
introduced to therapy during a split-night procedure were comparable to those found for
full-night titration studies, concluding that this did not appear to be an important
consideration in CPAP compliance. Although Strollo et al. (1996) also did not find a
significant difference in the rate of CPAP use between patients who had undergone
CPAP titration during a split-night procedure versus a full-night procedure, there was a
trend for persons in the fiill-night condition to use CPAP more on average per night (5.2
vs. 3 .8 hours per night); however, the authors caution that the study sample size was
small (n = 24). Because significant predictors and criteria for compliance have varied
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widely among studies, it is likely that long-term compliance with CPAP in OSAS
patients is determined by a variety o f factors (Pieters et al., 1996).
The variable and weak results that have been obtained in trying to predict CPAP
compliance from traditional objective sleep variables have been of limited value in
predicting CPAP compliance. Bennett et al. (1998) used the new computerized
techniques o f digital subtraction of video imagery (to detect subtle arousal-related
movements during sleep) and neural network EEG analysis (which examines sleep
depth on a continuous scale rather than the traditional sleep staging of Rechtschaffen
and Kales [1968] sleep scoring criteria) in an effort to find more sensitive measures of
sleep restfulness that might be useful in predicting CPAP compliance. In this mixed
sample that included patients with simple snoring through those having severe OSAS,
Bennett et al. (1998) found that compliance with CPAP treatment was significantly
correlated (r, = .39) with the movement event index, and with two measures of EEG
sleep depth (i.e., standard deviation of sleep depth and sleep descent index) derived
from the neural network analysis (r, = .47, r, = 48 respectively).
Research also indicates that subjective measures of CPAP satisfaction might
predict compliance with CPAP in OSAS patients (Hoffstein et al., 1992). Engleman et
al. (1996) specifically focused on subjective indicators o f effectiveness and compliance
and found that subjectively measured use of CPAP was significantly correlated with
pre-CPAP Epworth Sleepiness Scale scores (r = .22) and post-CP AP Epworth
Sleepiness Scale scores (r = -.18). Other important relations between self-reported
CPAP use and subjective indicators of improvement were derived from factor analysis
(Engleman et al., 1996). CPAP compliance was correlated with positive changes in
daytime functioning (r = .44), changes in nocturnal symptoms (r = .35), and changes in
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general functioning/symptoms (r = 46). Finally, a “nuisance factor” was associated
with reduced compliance (r =

1S), and was especially common in those with milder

illness (Engleman et al., 1996). In another study, Waldhom et al. (1990) observed that
compliant patients (i.e., using CPAP at the time of follow-up) had significantly more
subjective daytime sleepiness as assessed at baseline than noncompliant patients.
Rauscher et al. (1991b) found that significantly more OSAS patients who reported EDS
accepted CPAP compared to patients who reported little or no EDS. Furthermore,
Fletcher and Luckett (1991) found that more severe baseline obstructive sleep apnea
symptoms were significantly correlated with perceived improvement after treatment (r
= 62). Hoffstein et al. (1992) found that significantly more patients who reported no
subjective improvement with CPAP discontinued CPAP, which was in contrast to the
lower discontinuation rate of patients who reported subjective benefits from CPAP
therapy. Finally, Meurice et al. (1994) found that an improvement in a score of
subjective daytime sleepiness measured before and after CPAP treatment was
significantly correlated (r = -.40) with daily use of CPAP.
Side Effects and other Factors in CPAP Noncompliance
Though reports of serious complications for any mode of CPAP are rare, side
effects are very common (e.g., skin and eye irritation, nasal dryness and congestion, and
rhinorrhea, ATS, 1994). Hoffstein et al. (1992) found that waking up during the night
was the most common side effect and was reported by 46% of the sample. For patients
who refused CPAP after a titration trial, IS of 18 patients complained of having trouble
falling asleep with the CPAP mask on (Pieters et al., 1996). Lojander et al (1996) found
that six o f eight persons who refused CPAP after a night of CPAP titration reported that
did so because of failure to adjust to the machine. Intolerance o f the CPAP mask is a
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common complaint, with as many as 43% o f patients report discontinuing CPAP
therapy for this reason (Rolfe et al., 1991). Pepin, Leger et al. (1992) found that 50% of
patients using CPAP complained of at least one side effect due to the nasal mask.
Although Waldhom et al. (1990) found both compliant and noncompliant CPAP
patients had a high rate of reported adverse reactions to CPAP (discomfort with the
nasal mask was the most common), no significant difference between the groups was
demonstrated for any specific complaint. Side effects have been shown to be unrelated
to the number o f months CPAP was used as assessed at follow-up (Nino-Murcia et al ,
1989). Additionally, side effects have been shown to be unrelated to the pressure level
prescribed for home use (Pepin, Leger et al., 1992; Rauscher et al., 1993). Side effects
have also been shown to be unrelated to self-report of CPAP use (Engleman et al.,
1996). Nino-Murcia et al. (1989) found that 50% (n = 5) of patients who quit CPAP
within the first 2 weeks of initiating therapy did so because of anxiety. Hoffstein et al.
(1992) found that 10% of patients complained of claustrophobia from wearing the nasal
CPAP mask. Additionally, Kribbs et al. (1993b) found that feelings of claustrophobia
when wearing the CPAP mask were reported significantly more often by patients who
were irregular users o f CPAP (defined as using CPAP < 4 hours per for < 70% of days).
Interventions Aimed at Improving CPAP Compliance
Many of those who accept CPAP for treatment o f OSAS at home will
discontinue treatment, and such patients generally abandon this mode o f therapy in the
first three months (Collard et al., 1997; Hoffstein et al., 1992). It has been suggested
that the initial period o f adjustment to CPAP is the most crucial for compliance, because
many OSAS patients who accept CPAP therapy for home treatment quit in as little as 2
weeks (Nino-Murcia et al., 1989). Despite the fact that noncompliance with CPAP
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treatment in OSAS patients is a widely recognized problem, surprisingly few
interventions have been evaluated for improving CPAP compliance. Support in the
form o f weekly, followed by monthly telephone contacts was not shown to significantly
improve objective compliance for new CPAP users as compared to a control group of
chronic CPAP users (Fletcher & Luckett, 1991). Additionally, a study of CPAP use in
newly diagnosed OSAS patient by Hui et al. (2000) that also included support in the
form o f daily, followed by weekly and monthly telephone calls and that had participants
meet their physician after the first and second week o f CPAP therapy was not shown to
significantly improve compliance. Likar, Panciera, Erickson, and Rounds (1997)
showed improvement in hourly use of CPAP in patients who participated in one or more
(mean = 4) two-hour group education sessions held every six months, with an average
increase in nightly use of CPAP from 5.2 hours to 6.3 hours per night. Additionally,
education increased nightly use by at least two hours in 10 of 34 patients (29%).
Although these results are encouraging, the authors emphasized that there was no
control group, and the observed improvement may have been influenced by factors
other than the group education sessions (Likar et al., 1997). Chervin, Theut, Bassetti,
and Aldrich (1997) compared a group of patients with OSAS who received weekly
phone calls to troubleshoot and encourage CPAP use against a group patients who
received written information regarding the nature o f sleep apnea and the importance of
regular use of CPAP. Both interventions increased use as compared to a control group,
with average nightly use being 2.7 hours greater in the information group than in the
control group and 1.3 hours greater in the phone call group than in the control group,
although average nightly use was significantly increased only for the information group.
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These authors also found that intervention benefited patients most when it occurred
during the first month o f beginning CPAP (Chervin et al., 1997).
Habituation o f CPAP
Habituation is generally defined as a progressive decrease in the magnitude o f a
response that occurs with repeated presentations of an eliciting stimulus (Domjan,
1996). Habituation is a basic and common form of learning and is adaptive in the sense
that it allows organisms to ignore inconsequential stimuli (Petrinovich, 1984).
Furthermore, the habituation of a response represents a relatively permanent form of
learning, with observable short-term and long-term effects on behavior (Petrinovich,
1984). The behavioral opposite of habituation is sensitization, which was discovered
when existing theories o f habituation did not adequately account for all of the changes
that might occur in response to repeated presentations of a stimulus (Petrinovich, 1984).
Sensitization is generally described as an increase in the magnitude of a response
resulting from the repeated presentation o f a stimulus that also can also have short-term
and long-term effects on behavior (Domjam, 1996). According to the dual-process
theory, there are separate neural mechanisms or processes for habituation and
sensitization that act in opposition to regulate reflex responsivity (i.e., every stimulus is
thought to elicit a behavioral response which is the net effect of the competing
properties o f habituation and sensitization; Groves & Thompson, 1970). Habituation is
posited to occur in the stimulus-response (S-R) system, with sensitization thought to
occur in the state system (Groves & Thompson, 1970). The S-R system is involved in
the direct elicitation of a behavioral response by a stimulus (Groves & Thompson,
1970). The state system reflects the general level of arousal or tendency to respond and
may be influenced by stimuli other than the stimulus that originally activated the S-R
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system as well as the original stimulus. It is believed that mild to moderate stimulation
produces an initial increase in sensitization until a peak level is reached, which is
rapidly followed by a decay of the response. In general, sensitization is a transient
response, but may be prolonged when a stimulus is very salient or intense. The
processes of habituation and sensitization are influenced by the intensity, significance,
and timing of stimulus presentations, and both processes are hypothesized to decay with
time. Finally, responses to eliciting stimuli that have resulted in habituation are subject
to spontaneous recovery and dishabitution (Groves & Thompson, 1970).
Summary
Although there have been an appreciable number of studies that have attempted
to determine factors that influence CPAP compliance, inconsistent rather than
consistent predictors have been the norm. After ruling out the severity of the condition,
positive reinforcement, and economic reasons as explaining factors which influence
patient compliance with CPAP, Pieters et al. (1996) suggested that their habituation-like
method o f allowing the patients to gain experience with the CPAP device and slowly
adapt to positive airway pressure for two to four nights in the hospital prior to the
titration polysomnography may have resulted in a positive outcome, although this was
not tested experimentally. Other authors have emphasized the importance of the
manner that CPAP is introduced to the patient in the laboratory, although no scientific
evidence or specific information about how this should be accomplished was provided
(Sullivan & Grunstein, 1994). Furthermore, Saskin (1997) refers to the importance of
allowing patients to acquire experience with the CPAP stimulus with the blower set “on
a low pressure”, and states that this procedure is helpful for patients who are
uncomfortable with the idea of CPAP, but again, no data are provided. In an
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examination of split-night versus hill-night CPAP titration, Strollo et al (1996) reported
allowing all patients in the study to experience the CPAP stimulus prior to titration, but
did not examine this part of their procedure specifically.
Few studies have attempted to improve CPAP compliance with specific
interventions. The current study systematically evaluated the potential value of a
habituation procedure in promoting adjustment to CPAP in the laboratory, using a welldetailed habituation method, a properly controlled design, and the appropriate statistical
analyses. The current study attempted to fill a gap in the CPAP compliance literature
by examining the contribution of the manner in which patients were introduced to the
unique CPAP treatment stimulus and its influence on the acceptance and use of this
treatment for OSAS. Currently, there is no standard practice regarding the best way to
introduce patients to CPAP therapy, and methods vary widely across sleep disorders
centers. The CPAP habituation procedure consisted of a 30-minute trial during which
patients were acclimated to CPAP while experiencing a range of pressures using a
standard nasal mask prior to undergoing CPAP titration in the laboratory. Allowing
patients to experience CPAP prior to polysomnography with CPAP titration, while they
were engaged in typical pre-sleep activities such as watching television or reading, was
hypothesized to make the CPAP stimulus less arousing during sleep. Information about
CPAP is a valuable resource for patients, but it was hypothesized that in vivo
experience with the CPAP apparatus would produce better CPAP compliance post
polysomnography. Undoubtedly, many sleep disorders centers provide information
about CPAP and allow patients to experience CPAP before treatment; however, there
have not been a published scientific study that has specifically examined the role of
patients’ initial experience with the CPAP stimulus in the laboratory to treatment
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outcome. Given the potential health problems associated with untreated OSAS, the
efficacy of CPAP treatment for OSAS, and the lack of good treatment alternatives,
identifying a method to improve CPAP compliance warranted exploration.
In summary, habituation o f CPAP prior to the polysomnography was
hypothesized to facilitate the initial adjustment to the treatment, which was
hypothesized to be reflected in the sleep architecture during the time of CPAP titration.
Improved initial adjustment to the CPAP treatment stimulus was hypothesized increase
the acceptance of CPAP and the degree o f individual hourly compliance with CPAP
therapy for the treatment of OSAS.
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Methods
The CPAP habituation study was designed to test the general hypothesis that
habituation to the CPAP treatment stimulus prior to attempting to sleep with CPAP
would promote the acceptance and use of this form of treatment for OSAS. All
participants were scheduled to undergo some form of polysomnography (i.e., split-night
or fiill-night CPAP titration procedure), in a medical sleep disorder center on the night
of their participation in the study. The study consisted of two experimental groups and
two control groups. Participants in the two experimental groups wore the nasal CPAP
mask during wake and experienced a range o f air pressures over a 30-minute trial on the
evening that their sleep studies were conducted. This occurred prior to the clinical
polysomnography. All participants, including those in the two minimal treatment
control conditions, received information (see Appendix A) regarding the seriousness of
OSAS, the effectiveness o f CPAP in treating this condition, and the benefits that they
could expect to derive from using CPAP regularly. Participants undergoing the CPAP
habituation procedure received this information also because withholding information
about such a serious medical problem would not have been in their best interest.
Participants
Of the total o f 144 participants that were recruited for the study, 61 participants
met inclusion criteria for the data analyses. Participants were patients referred to the
Sleep Disorders Center of Alabama (SDA), the HealthSouth Medical Center Sleep
Disorders Center (HMC), or the Sleep Disorders Center of the Ochsner Clinic o f Baton
Rouge (OCBR) for a clinical polysomnography (PSG). The purpose of the clinical PSG
was to rule out the presence of OSAS with the possibility o f CPAP treatment during the
study, or in the case o f patients newly diagnosed with OSAS, to undergo a full-night
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CPAP titration trial. Participants were approached in the laboratory on the night of their
sleep study to determine if they were interested in participating in the experiment.
Participants were fully informed about the purpose and nature o f the study in
accordance with the ethical guidelines of the American Psychological Association
(1992) prior to their participation. The participants signed appropriate consent forms
(see Appendixes B, C, and D) before any experimental procedure was undertaken.
Participation was voluntary, and participants were informed that they could discontinue
their participation at any time during the study without penalty. All participants
included in the final data set experienced a CPAP titration trial during the course of the
clinical PSG on the same night of their participation in the experiment. The
experimenter informed the participants of the potential benefits that might result from
participating and of the scientific knowledge that might be derived as a result of their
participation in the experiment. Participants were followed up after they had been on
CPAP treatment at home for an average o f approximately seven weeks, at which time
objective electronic or time counter data was collected from their CPAP device by a
representative of the sleep disorders center.
Although an A+HI o f at least five per hour meets the diagnostic criterion for the
minimum number of events that is required per hour asleep for OSAS, only participants
with an A+HI o f at least 10 per hour were included in the study. This inclusion
criterion was chosen in light o f the current scientific literature, which shows that serious
health consequences of OSAS are most likely in those with an A+HI of 10 or more per
hour. Any subject deemed eligible to receive CPAP treatment by the referring
physician was eligible for either of the experimental conditions. Chart reviews were
conducted to screen for presenting complaints o f loud and persistent snoring, EDS, and
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reports o f respiratory pauses during sleep to find appropriate candidates for the study.
Participants were not eligible for the study if they have had any previous first hand
experience with CPAP or BiPAP. All appropriate candidates were randomly assigned
to the experimental or control condition by means o f a coin toss. Physicians assigned
participants to the split-night or full-night titration condition based upon a clinical
evaluation. Because three laboratories were employed to recruit and run participants, an
effort was made to maintain a balance between the number of participants participating
form each sleep disorder centers. However, extenuating circumstances resulted in
relatively fewer participants coming from the OCBR. Men and women were eligible to
participate in the study.
Procedure
Four groups o f participants were utilized in the experiment. Please refer to
Table 1 for a description o f the experimental conditions, which will be followed by a
Table 1: Description o f the Groups and Relevant Procedures___________________
Split-Night Titration
Full-Night Titration
Habituation/Education

Education

Group 1: Hab/Ed-SN
Standardized Education
CPAP Habituation
Split-Night CPAP Titration
Group 3: Ed-SN
Standardized Education
Sleep Disorders Inventory
Split-Night CPAP Titration

Group 2: Hab/Ed-FN
Standardized Education
CPAP Habituation
Full-Night CPAP Titration
Group 4: Ed-FN
Standardized Education
Sleep Disorders Inventory
Full-Night CPAP Titration

more detailed explanation of the procedures for each group, in the text. The number o f
participants for each group varied from the proposed number. The proposed n per
group o f 23 was not achieved for any of the groups. The number per group in the split39
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night conditions approached the proposed number of participants (Hab/Ed-SN = 22,
Ed-SN = 21). However, participants for the full-night conditions were scarcer than had
been anticipated, and as a result, an n o f only nine per group was achieved (Hab/Ed-FN
= 9, Ed-FN = 9). The proposed number o f participants per group for the nightly CPAP
use data analysis was derived from a consideration of a nominal alpha level of .05, an
acceptable power o f .80 (beta = .20, no more than four times alpha), two treatment
levels, and an estimated effect size equal to one. The minimum number o f participants
needed per cell to avoid an excessive chance of a Type Q error was derived from Table
C. 12 o f Hinkle, Wiersma, and Jurs (1994). Although 17 participants was the exact
number listed, 23 per group were proposed because the CPAP treatment literature
suggested that only about 75% o f all participants would elect to embark upon CPAP
therapy after a undergoing CPAP titration in the sleep laboratory, and that 23
participants per group would be needed to include at least 17 per group for the nightly
CPAP use data analysis. The effect size chosen was based on limited information
regarding average daily use of CPAP. The average CPAP use in new patients across
studies has been shown to be approximately five hours per night with standard
deviations o f approximately one hour being common. Therefore, in order for this study
to have had practical significance, it was predicted that CPAP use should be increased
by at least one hour per night on average in those who had undergone CPAP
habituation. Further, interventions such as information and education sessions about
CPAP have been shown to increase use by at least one hour per night, based on the a
review o f the CPAP treatment literature.
After they had given their written informed consent to participate, all
participants were presented with the written educational briefing contained in Appendix
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A regarding obstructive sleep apnea syndrome and its treatment with CPAP. The sleep
laboratory directors approved the written CPAP education, and participants received the
written educational briefing prior to experiencing any of the other procedures. After the
experimenter had presented the consent form and the written information, any questions
that the participant had regarding the procedure or the nature of the research were
answered at that time. At the conclusion of the educational briefing, participants in the
two CPAP habituation groups (Hab/Ed-SN, Hab/Ed-FN) were fitted with a standard
nasal CPAP mask and underwent the habituation procedure. The proper mask size was
ensured through the use of a measuring device manufactured by the Respironics
Corporation. Following this, participants in the CPAP habituation groups placed the
nasal CPAP mask (which was attached to the CPAP system with a hose) over his or her
nose, and the experimenter affixed the mask with a headgear that consisted of a web of
four straps that looped through slots in the CPAP mask and wrapped around the
participants head. Next the experimenter informed the participants that the CPAP
device was going to be switched on, and they were instructed to breathe normally
during CPAP. To ensure that all participants experienced the exact CPAP habituation
pressures described, an air leak detection device contained in the CPAP
monitoring/control system was used to evaluate the quality of the seal of the mask with
the face. If the leak was below a value of 20 milliliters per minute, the mask was
considered a good fit, and deemed as delivering the correct pressure. The trial was
considered to have begun when the machine was switched on.
Participants in the two Hab/Ed groups experienced a range of CPAP pressures in
a systematic fashion while awake. Pressures o f 4 cm H 20 through 10 cm H 20 were
used. Patients began the trial at 4 cm H 20, as this was in accordance with the usual
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starting CPAP pressure that patients were introduced to during a typical titration
procedure. Pressure was increased in increments of 2 cm H 20 every 7.5 minutes until
each patient spent 7.5 minutes at 10 cm H20, and the CPAP habituation procedure
lasted a total of 30 minutes with the mask on and delivering pressure. The final
pressure of 10 cm H 20 was selected because a review of the literature revealed that the
average prescribed pressure for CPAP across laboratories was approximately 10cm
H20 (e.g., Ferguson et al., 1990; Lojander et al., 1996; Pieters et al., 1996; Waldhom et
al., 1990). The experimenter was present with the participants during the CPAP
habituation procedure (with the exception of leaving the room briefly to adjust the
CPAP pressure) to monitor for indications that the study should have been discontinued
(e.g., panic-like response, severe discomfort), to ensure that participants remained
awake, and to confirm that participants were wearing the CPAP mask properly during
the procedure. All participants were instructed that they would be informed o f each
pressure increase before it occurred and that they could request that the pressure be
lowered to the previous level if they had difficulty tolerating a pressure increase. The
experimenter asked the participants to give a hand signal (a thumbs up) after each
pressure increase to indicate that the trial should continue at the new pressure. If
participants indicated that they were experiencing discomfort in response to a pressure
increase, the pressure was lowered to the previous level, and they were encouraged to
keep the mask on for the remainder of the 30-minute trial while continuing at the
highest pressure that had been well-tolerated. This was done so that all participants
included in the data analysis had an equal number of minutes of experience with CPAP
prior to their sleep study. However, the participants were informed that they could
discontinue the trial if they remained uncomfortable after returning to the previous
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CPAP pressure level. Participants were allowed to engage in any reasonable distracting
activity that they chose during the procedure (e.g., watching TV, reading magazines).
The experimenter spent approximately 45 to 60 minutes with each patient in the each of
the study groups, including the completion o f the informed consent. All participants
were debriefed informally following the CPAP habituation trial to determine if they had
any comments or questions regarding the CPAP habituation procedure.
The CPAP education groups (Ed-SN, Ed-FN) were minimal treatment control
groups that did not undergo the habituation procedure. These participants were
provided with information regarding the consequences of untreated sleep apnea and the
benefits o f undertaking CPAP therapy for the treatment of obstructive sleep apnea. In
order to account for time spent with the experimenter as a potential confounding
variable that could account for a positive outcome in the experiment, the experimenter
spent an equal amount o f time interacting with the control participants. The control
participants spent their time answering questions about their sleep problems with the aid
of the Sleep Disorders Inventory (SDI, Waters, unpublished; see Appendix E).
The only different pre-PSG information which the CPAP education control
participants were given was that they were told they would be participants in an
experiment who would undergo the usual laboratory procedures and would be
compared to a second group of participants who would undergo a different procedure to
determine if it would help this second group adjust to CPAP better. The CPAP
education control participants were also told that the additional information that they
provided to questions of the SDI might potentially provide a better understanding of
adjustment to CPAP. In accordance with the normal procedures in the participating
sleep disorders centers, all persons undergoing a sleep study with the possibility of
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CPAP were given the opportunity to get in vivo experience with the CPAP apparatus
before undergoing their sleep study. The usual laboratory procedure was to fit persons
with a nasal mask if they desired and to use the starting pressure of 4 cm CPAP pressure
only. After 10 minutes, the sleep laboratory technician asked these participants if they
wished to continue to experience CPAP or if they were satisfied and wished to
discontinue. The CPAP education control participants could experience CPAP as much
or as little as they desired.
Following their pre-PSG participation, each patient underwent the standard PSG
procedures o f a split-night or full-night CPAP titration in the sleep disorders centers.
Sleep parameter data was collected in a accordance with the standard o f practice. All
participants had electroencephalogram (EEG) electrodes (Grass Instrument silver/silver
chloride cup electrodes, 8 mm) placed according to the 10-20 international placement
system. Leads were attached for C4, C 3 ,0 2 ,0 1 , A2, A l, electrooculogram (EOG),
and submental electromyogram (EMG). C3 and C4 optimally record sleep spindles and
delta waves, and the 01 and 0 2 placements (located above the occipital regions) are
particularly useful in detecting the presence of alpha rhythm and determining sleep
onset (Guilleminault, 1982). The EOG placements were referenced to Al and A2
(neutral sites located on the mastoid process). In addition to scalp and face electrode
placements, EMG electrodes were attached to the anterior tibialis muscles of the left
and right legs to detect periodic limb movements, which, if they occurred, may have
resulted in associated arousals which could have confounded the transient arousal data.
Respiration was be recorded with thermistors (nasal and oral airflow) and two
respiration belts (respiratory effort) to detect the presence o f any sleep-related breathing
disorders. All sleep periods were scored according to Rechtschaffen and Kales’ (1968)
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sleep stage scoring criteria. Arousals were scored according to the American Sleep
Disorders Association (1992) criteria.
Variables of interest in evaluating the effectiveness of the pre-sleep habituation
procedure on sleep quality during CPAP titration included: (1) sleep onset latency
(SOL; time elapsed from lights out to 3 consecutive epochs of unambiguous sleep or
one epoch o f sleep with a K-complex or sleep spindle); (2) percent stage 1 NREM sleep
(% 1NREM); (3) percent combined stages 3 and 4 NREM sleep or slow wave sleep
(SWS); (4) percent rapid eye movement sleep (REM); (5) number o f spontaneous
transient arousals per hour asleep (STA); (6) number of awakenings per hour in bed
(No. Awake); and (7) sleep efficiency, the percent o f time asleep of the total time in bed
(SE). CPAP compliance data was recorded by means of a microprocessor units built
into the Sullivan Elite model CPAP machine and the Respironics Encore model CPAP
machine, or a digital time counter in the case of the Fisher & Paykel model CPAP
machine. Participants were made aware that their CPAP machines would record their
CPAP usage and that their data would be examined after they had used CPAP for
several weeks. Data were downloaded or read from each participant’s CPAP machine
by home healthcare representatives during the routine follow-up visit or were obtained
via mail in the form of electronic data storage cards that the participants removed from
their CPAP machines and mailed to the OCBR. The variable of interest for the
approximately seven-week follow-up was the mean number of hours CPAP was used
each day.
Data Analyses
Analysis #1: Comparison of the demographic characteristics of the sample.
Demographic Variables. (1) pre-treatment A+HI, (2) BMI, and (3) age.
45

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

One-way ANOVA was used to compare group means for demographic measures
to determine if there were any significant groups differences that might need to be taken
into account during the interpretation of the results of the study.
Analysis #2: Effect o f CPAP habituation on sleep during the CPAP titration PSG.
Dependent Variables: (I) SOL, (2) % 1NREM, (3) % SWS, (4) % REM, (5) STA, (6)
No. Awake, and (7) SE.
The following experimental hypotheses were tested:
1. The SOL during the CPAP titration will be significantly less for participants in the
Hab/Ed groups (Hab/Ed-SN, Hab/Ed-FN) as compared to participants in the Ed
groups (Ed-SN, Ed-FN)
2. The % 1NREM sleep during CPAP titration will be significantly less in the Hab/Ed
groups as compared to the Ed groups.
3. The STA during CPAP titration will be significantly less in the Hab/Ed groups as
compared to the Ed groups.
4.

The No. Awake during the CPAP titration will be significantly less in the Hab/Ed
groups as compared to the Ed groups.

5. The % SWS during CPAP titration will be significantly greater in the Hab/Ed
groups as compared to the Ed groups.
6. The % REM during CPAP titration will be significantly greater in the Hab/Ed
groups as compared to the Ed groups.
7.

Sleep efficiency will be significantly greater during CPAP in the Hab/Ed groups as
compared to the Ed groups.
Separate one-way MANOVAs were conducted to compare the treatment versus

control group means (Hab/Ed vs. Ed) for the sleep variables (with the exception of
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STA) in the split-night and full-night conditions. The Hab/Ed vs. Ed comparisons for
split-night and full-night conditions were compared separately because the sleep
architecture varies across the night, with the % REM increasing and the % SWS
decreasing throughout the night, and split-night participants slept with CPAP during the
second half of the night when % REM tends to be higher and % SWS tends to be lower
than in the first half of the night. Another important reason for analyzing the split-night
and full-night conditions separately was to account for the first-night effect (Agnew,
Webb, & Williams, 1966), which are consistent changes in sleep architecture that are
attributable to the novel sleeping environment of the laboratory with its recording
apparatus. Therefore, the adjustment to sleep in the laboratory would likely be more
evident in the sleep architecture of the split-night participants. Pearson’s correlation
coefficients were computed between the sleep quality and quantity variables to
determine if they were significantly correlated for use in MANOVA. Alpha was set at
the traditional significance level of p < OS for all tests. It was specified that if a
MANOVA were significant, individual one-way ANOVAs (Hab/Ed vs. Ed) would have
been conducted for each o f the dependent variables to identify specific differences
between the group means. The STA was examined separately with t-tests comparing
the split-night and full-night conditions separately because data was not available for
several participants due to the loss o f electronic data at the SDA and the HMC.
Analyzing the STA separately allowed a larger n for each of the respective MANOVA
tests. Alpha was set at the traditional significance level of p < .05.
Analysis #3: Effect o f CPAP habituation on the initial acceptance of CPAP for home
treatment of OSAS.
Dependent Variable: the proportion o f acceptance of CPAP treatment for each group.
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The following experimental hypothesis was tested: Acceptance o f CPAP will be
significantly greater in the Hab/Ed groups as compared to the Ed Groups. Acceptance of
CPAP was defined as a participant agreeing to take home a CPAP device with
instructions to use on a nightly basis (or during each sleep period) to manage his or her
OSAS.
Separate tests o f proportions were conducted to examine acceptance of CPAP in
the split-night (Hab/Ed-SN vs. Ed-SN) and full-night (Hab/Ed-FN vs. Ed-FN)
conditions to determine if severity o f OSAS had an influence on acceptance. A chisquare test o f independence was used to compare CPAP acceptance in the Hab/Ed-SN
versus Ed-SN following polysomnography with CPAP titration in the laboratory. The
alpha level was set at p < .05 as the criterion to reject the null hypothesis that
acceptance of CPAP was independent of group assignment. Fisher’s exact test was
used to compare acceptance for the Hab/Ed-FN versus Ed-FN due to the small number
o f participants in these groups. The alpha level was set at p < .05 as the criterion to
reject the null hypothesis that acceptance of CPAP was independent of group
assignment. Because the tests were not significant as predicted, a chi-square test of
independence comparing the rates o f acceptance of the Hab/Ed groups versus the Ed
groups was conducted to examine the overall proportion o f CPAP acceptance collapsed
across titration conditions.
Analysis #4: Effect o f CPAP habituation on the degree o f compliance.
Dependent Variable: the mean number of hours per day of CPAP use as measured at
approximately a seven-week follow-up.
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The following experimental hypothesis was tested: The Hab/Ed-SN and the Hab/Ed-FN
groups will have significantly more mean hours of daily CPAP use than the Ed-SN and
Ed-FN groups.
A two-way ANCOVA (Hab/Ed vs. Ed x SN vs. FN) test was conducted to
compare the groups for the nightly mean number of hours of CPAP use, with the pretreatment A+HI and gender as covariates. Proposed covariates were the pre-treatment
A+HI, age, BMI, and gender, but only pre-treatment A+HI and gender were used as
covariates after it was revealed that age and BMI had little bearing on CPAP use (please
see the results section). For participants in the full-night titration conditions, the A+HI
value was derived from the baseline diagnostic polysomnography. The pre-treatment
was proposed as a covariate because persons undergoing split-night CPAP titration are
likely to have more severe OSAS than persons undergoing full-night CPAP titration,
and one of the principal aims o f the study was to test whether CPAP habituation
increased CPAP compliance regardless of illness severity. Alpha was set at the
traditional significance level of p < .05.
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Results
The objective o f the investigation was to evaluate a CPAP habituation method
for introducing OSAS patients to CPAP therapy by determining its effects on sleep
during CPAP, and its effects on subsequent acceptance and compliance with CPAP
treatment. It was predicted that participants in the CPAP habituation treatment groups
would have better sleep quality during the CPAP titration, would be more likely to
accept CPAP for a trial o f treatment at home, and would be more compliant with
treatment in terms o f average daily use of CPAP at follow-up, than participants in the
CPAP education control groups.
Analysis of the Demographic Data
Data from 61 participants were examined in the analyses, and a total of 48
(78.7%) men and 13 (21.3%) women were included in the final sample. The sample
was 91.8% White (n = 56) and 8.2% African American (w = 5). The majority of the
sample (83 6%) was recruited from the two sleep laboratories in Birmingham, Alabama,
and approximately an equal number of persons participated from the SDA (n = 25) and
the HMC (n = 26). The remainder of the sample (16.4%) participated at the OCBR

(n - 10). Means and standard deviations were computed for the complete sample for
the variables of age, BMI, and pre-treatment A+HI, which can be found in Table 2. On
average, members of the sample were middle-aged, obese, and had severe OSAS.
Table 2. Demographic Characteristics of the Complete Sample (N= 61)
Variable
M
Range
0SD)
Age
47.38
(10.49)
26-75
BMI

34.18

(9.29)

19.4 - 76.8

A+HI

45.81

(29.65)

10.0 - 130.7

50

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Split-night CPAP titration was administered to 43 (70.5%) participants, and full-night
CPAP titration was administered to the remaining 18 (29.5%) participants by PSG
technicians.
Demographic data were examined to determine if there were statistically
significant group differences for any of the demographic measures that might need to be
taken into account when interpreting the results. One-way ANOVAs, with the GamesHowell multiple comparison test (see below), were used to compare the four groups for
statistically significant differences on the demographic variables of age, BMI, and pre
treatment A+HI. Means and standard deviations can be viewed in Table 3.
Table 3. Demographic Comparisons by Group
Hab/Ed-SN
Ed-SN
M
(,SD)
M
(SD)
Variable
49.18 (10.46) 47.19 (11.96)
Age

Hab/Ed-FN
M
(SD)
43.11 (10.51)

Ed-FN
M
(SD)
47.67 (6.42)
36.53

BMI

33.05

(5.14)

37.12 (12.21)

27.71

A+HI

52.62 (27.76)

54.26 (33.08)

21.60 (10.42)

(6.68)

(8.96)

35.31 (28.37)

A one-way ANOVA that compared Age among the four groups was not
significant [F(3, 57) = 0.71,/? = .552 ]. The observed power at a = .05 for the test was
.19. A one-way ANOVA for BMI among the four groups was not significant [F (3, 57)
= 2.67, p = .056], The observed power at a = .05 for the test was .62. A one-way
ANOVA that compared the pre-treatment A+HI among the four groups was significant
[F (3, 57) = 3.97, p - .012], A Games-Howell multiple comparison test was used
because the homogeneity o f variance assumption was untenable for the pre-treatment
A+HI, and revealed that participants in the Hab/Ed-FN group had a significantly lower
mean pre-treatment A+HI than participants in Hab/Ed-SN (p < 0 0 1 ) and Ed-SN

{p = .002) groups. The observed power for the test at a = .05 was .81.
51

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

A Chi-square test of homogeneity was conducted to examine if unequal
proportions o f men and women participated in the split-night and full-night conditions.
This revealed a statistically significant difference for the number males and females in
the titration conditions )?{df= 1, N = 61) = 17.86,/; < .001. Most of the male
participants (83 .3%) participated in the split-night titration condition, and the most of
the female participants (76.9%) participated in the full-night titration condition. A Chisquare test of independence conducted to examine if unequal proportions of men and
women participated in the treatment and control conditions was not significant, £ { d f =

\ , N = 61) = 0.06, p = .806. The results for all proportions are presented in Table 4
Table 4. Comparison of the Number of Participants per Condition by Gender
Condition
Male
Female
Significance
**
Titration
SN
40
3
1786
1
p< .001
FN
Group
Hab/Ed
Ed

8

10

24

7

24

6

.06

1

p = 806

Analysis o f the PSG Sleep Variables during the CPAP Titration
Means and standard deviations were calculated for the purpose of comparison of
the polysomnographic dependent variables for the habituation treatment and education
control participants. The split-night and full night conditions were separated for these
comparisons because of well-established differences in the sleep architecture across the
night. These can be viewed in Table S and Table 6. Again, because of differences in
the composition o f the sleep architecture across the night, the data for full-night and
split-night groups were examined separately. For the purpose of examining the effect of
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Table 5. Descriptive Statistics for the Sleep Architecture: Split-Night
Hab/Ed-SN
n
Ed-SN
n
Variable
M
(SD)
M
(SD)
SOL
11.77 (17.41)
22
14.31 (13.87)
21
SE

82.90

(10.64)

22

84.21

(10.38)

21

%Stagel

10.17

(6.66)

22

12.52

(12.62)

21

%SWS

10.26

(11.23)

22

7.57

(8.83)

21

%REM

20.95

(11.64)

22

20.40

(13.53)

21

No. Awake

2.96

(1.82)

21

3.37

(1.97)

21

STA

4.74

(5.06)

17

6.89

(8.30)

20

Table 6. Descriptive Statistics for the Sleep Architecture: Full-Night
n
Ed-FN
n
Variable
Hab/Ed-FN
M
(SD)
M
(SD)
SOL

8.61

(11.21)

9

13.22

(13.18)

9

SE

87.38

(16.31)

9

80.44

(11.51)

9

%Stagel

4.17

(3.46)

9

9.76

(7.03)

9

% sw s

21.14

(17.95)

9

14.28

(12.24)

9

%REM

16.81

(518)

8

14.29

(7.17)

8

No. Awake

1.82

(.92)

8

2.82

(1.68)

9

STA

2.83

(2.71)

7

4.36

(2.35)

5

CPAP habituation on sleep during the CPAP titration, MANOVAs were used to
compare the PSG variables between the treatment and control participants (i.e., Hab/EdSN vs. Ed-SN; Hab/Ed-FN vs. Ed-FN). Pearson correlation coefficients were computed
to examine associations among the PSG sleep variables and are given in Appendixes F
andG. The results for one-tailed MANOVAs are contained in Table 7. Neither of the
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MANOVA analyses was statistically significant at the a = .05 level of significance.
The observed power at a = .05 for both MANOVAs was . 14. The MANOVAs included
all of the PSG sleep variables with the exception o f STA, which was not included due to
Table 7. Examination o f Habituation versus Education Sleep Architecture during
CPAP with MANOVA
P
Titration
F
Hotelling’s T2
df
.45
Split-night
2.48
36
6,35
Full-night

5.92

.61

6,8

.36

a large number of missing data points, and consequently, was analyzed separately. A
one-tailed t-test that compared STA between the Hab/Ed-SN and Ed-SN groups was not
significant [/ (35) = 0.93, p = .18], The observed power for the test at a = 05 was .15.
A one-tailed t-test that compared STA between the Hab/Ed-FN and Ed-FN groups was
not significant [/(10) = 1.02,/? = .17], The observed power for the test at a = .05 was
.15.
Analysis of the Effect o f CPAP Habituation on Acceptance of CPAP
Forty-nine participants (80.3%) accepted CPAP for a trial of treatment at home.
The chi-square test o f independence and Fisher’s exact test (for the full-night
comparison) were used to determine if acceptance of CPAP was independent of the
group assignment. Acceptance o f CPAP was examined separately between the splitnight and full-night groups to determine if the severity o f OSAS had an influence on
acceptance. A chi-square test of independence was not statistically significant,
1, N= 43) = 0.09, p = .767, for a comparison o f the proportion of participants accepting
CPAP in the Hab/Ed-SN and Ed-SN groups. Also, Fisher’s exact test was not
statistically significant (p = .206) for a comparison o f the proportion of participants
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accepting CPAP in the Hab/Ed-FN and Ed-FN groups. The split-night and full-night
conditions were collapsed across treatment conditions after it was determined that
severity of OSAS did not have significant bearing on acceptance of CPAP, and a Chisquare test o f independence computed to evaluate whether unequal proportions of
participants accepted CPAP in the habituation treatment and education control

= 61)= 1.50,/j = 2 2 1 . Refer to Tables

conditions. The test was not significant
8,9, and 10 for exact proportions.

Variable

Treatment

Control

17

17

5

4

CPAP
Accept
Reject

i
.09

df

Significance

1

p = .767

Treatment

Control

Significance

CPAP
Accept

6

9

p = .206

Reject

3

0

Variable

Table 10. Chi-square Test of Independence for CPAP Acceptance: Complete
Sample
df
Significance
Variable
Treatmeni
Control
CPAP
Accept
Reject

23

26

8

4

1.50

I

p = .221

Analysis o f the Effect o f CPAP Habituation on the Nightly Use of CPAP
Follow-up data for average nightly CPAP use was available for 44 (89.8%)
participants who accepted CPAP for a trial of OSAS treatment at home. Data were
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available for 33 men and 11 women. Means and standard deviations were computed for
each o f the four groups in terms of hours of use per night and can be found in Table 11.
Pearson product-moment correlations were computed between proposed potential
demographic covariates (age, A+HI, BMI, and gender) and CPAP use to determine if
there were significant correlations between the proposed covariates and CPAP use.
Table 11. Mean Hourly Use o f CPAP per Night
M
(SD)
Group

Range

n

Hab/Ed-SN

5.07

(2.34)

0 .7 5 -7 .9 2

15

Ed-SN

5.26

(176)

0.37 - 7.47

14

Hab/Ed-FN

2.71

(1.93)

0 .6 7 -3 .7 8

6

Ed-FN

4.42

(2.07)

1.48-8.48

9

Additionally, titration type and CPAP acceptance were included in correlation analyses
of variables relevant to the examination of CPAP use in the current study. These
correlations can be viewed in Appendix H. There were statistically significant pointbiserial correlation coefficients between gender and CPAP use (rp&= 33, p = .03),
gender and A+HI (rPb= .36, p = .005), titration type and A+HI (rp* = .40, p = 001), and
titration type and CPAP use (/>* = .32, p = .036). Men tended to use CPAP more per
night than women, and men tended to have a higher pre-treatment A+HI than women.
Also, participants in the split-night groups tended to use CPAP more per night than
participants in the full-night groups, and participants in the split-night groups tended to
have a higher pre-treatment A+HI than participants in the full-night groups.
Additionally, there was a statistically significant Pearson phi coefficient between gender
and titration type (<t>= .54., p < .001), as men tended to be assigned to the split-night
condition, and women tended to be assigned to the full-night condition by the clinic
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physicians. Finally, a t-test that was computed to assess for a possible gender difference
among CPAP use was statistically significant [/ (42) = 2.24, p = .03] and revealed that
men used CPAP {M= 5.08, SD = 2.00) an average of 1.61 hours more per night than
women (M= 3 .47, SD = 2.24). The observed power for the test at a = .05 was .59.
A two-way ANCOVA (Hab/Ed vs. Ed x SN vs. FN) was used to compare the
mean number of hours of daily CPAP use with pre-treatment A+HI and gender as
covariates. Gender was included as a covariate because of the observed statistically
significant correlation between gender and CPAP use and the statistically significant
difference for CPAP use between men and women, and A+HI was included as a second
covariate because o f the statistically significant difference for A+HI between the
Hab/Ed-FN group and the split-night groups. The covariate of baseline A+HI was not
significant (F [1, 38] = 0.08, p = .781). The observed power for the test at a = 05
was. 06. The covariate of gender was not significant (F [1, 38] = 1.86, p = .181). The
observed power for the test at a = .05 was .27. There were no statistically significant
main effects for treatment (F[l, 38] = 1.91,/; = .175) or titration type (F [l, 38] = 1.76,

p = . 192). The observed power for the tests o f main effects at a = .05 was .27 and .25
respectively. The interaction was not significant (F [I, 38] = 1.45, p = .236). The
observed power for the tests at a = .05 was .22.
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Discussion
The CPAP habituation procedure plus CPAP education was not shown to be
superior to CPAP education alone, the community standard of care for introducing
OSAS patients to CPAP therapy. In other words, CPAP habituation did not add
anything to CPAP education as a means of increasing CPAP compliance, and no
statistically significant differences were observed between participants in the CPAP
habituation treatment groups and the education control groups for any of the dependent
variables. There were several factors that might have influenced the outcome of the
study that will be presented after a discussion of the results.
An examination o f the polysomnographic data showed that the sleep architecture
of the CPAP habituation treatment and the education control participants was not
significantly different for either the split-night or full-night conditions, thus
demonstrating no statistically significant advantage to persons who experienced CPAP
habituation. Because there were no significant differences for age, BMI, or the A+HI
between treatment and control groups in the same titration condition, it does not appear
that any o f the demographic variables had an influence on the polysomnographic data.
Polysomnographic variables that had not been previously examined during split-night
CPAP titration, such as awakenings per hour in bed, transient arousals per hour asleep,
and sleep onset latency during CPAP, also were not significantly different between
participants in the CPAP habituation treatment and education control groups. This is
consistent with the CPAP compliance literature, in which only weak correlations have
been reported between polysomnographic parameters and various definitions of CPAP
compliance. The lack o f significant results might provide additional support that
polysomnographic parameters have limited linkage with CPAP compliance. Although
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there were no statistically significant differences for the PSG variables, the values for
sleep quality and sleep quantity variables were in the direction predicted by the
hypotheses, with the only exception being that participants in the Ed-SN group had nonsignificantly higher sleep efficiency than participants in the Hab/Ed-SN group. An
inspection of the PSG variables revealed that for most comparisons, the differences
were small, and there was a large degree of variability in the data, as the standard
deviations for most variables were large, and were larger than the means for many
variables in the split-night data. Additionally, the differences were so small that it is
unlikely that they would have been would be clinically meaningful even if they were
reliable. However, given that the observed power for the MANOVAs was low (. 14), a
lack of sufficient statistical power might account for a lack of significant findings,
which will be discussed below.
Persons who experienced CPAP habituation were not shown to be more likely to
accept CPAP than those who experienced the normal laboratory educational procedures
for introducing OSAS patients to CPAP. In an examination o f the complete sample, the
percentage of persons who accepted CPAP (80.6%) after experiencing CPAP titration in
the laboratory was similar to that found in the treatment literature (76%, Pieters et al.,
1996; 63%, Strollo et al., 1996; 78%, Fleury et al., 1994; 72%, Rauscher et al., 1993;
83%,Waldhom et al., 1990). Additionally, although small in number and not
statistically significant, twice as many participants who experienced CPAP habituation
(n = 8) rejected CPAP after a night o f titration than participants who experienced
education only (n = 4). This difference for CPAP acceptance is largely accounted for
by the performance o f persons in the Hab/Ed-FN group, in which three persons rejected
CPAP. In regard to the three individuals who rejected CPAP as a treatment option,
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evidence suggests that persons with milder OSAS are less likely to accept CPAP
treatment (Rauscher et al., 1991). However, CPAP acceptance in the Hab/Ed-FN group
raises the possibility that sensitization to the treatment stimulus might have occurred as
opposed to habituation, which will be discussed below.
An examination of nightly use o f CPAP after sn average follow-up period of
49.1 days did not reveal any advantage for CPAP habituation. The mean of 4.68 (SD =
2.16) hours o f CPAP use per night for the complete sample was similar to data for
nightly CPAP use in the CPAP compliance literature (M = 4.7, Engleman et al., 1994;

M = 4.9, Rauscher et al., 1993; M = 4.7, Reeves-Hoche et al., 1994). Nightly CPAP use
of at least four hours was achieved by 61.4% (n = 27) of the sample, and use of at least
five hours o f use per night was achieved by only 56.8 % (n = 25) of the sample.
Although not statistically significant, split-night participants used CPAP an average of
1.43 hours more per more night than full-night participants, which is a clinically
important difference. This difference might be best accounted for by severity of OSAS
in terms o f the diagnostic A+HI, which has been shown to be significantly correlated
with nightly CPAP use (Bennett et al., 1998; Hui et al., 2001; Meurice et al., 1994).
Although there was no significant correlation between CPAP use and the baseline A+HI
in the current study, there was a significant correlation between titration condition and
CPAP use, and assignment of the titration condition was based on severity. Several
other correlations were significant. Overall, the pattern of significant correlations
suggests that there was an association between gender, OSAS severity, and titration
type, with women having less severe OSAS, being more likely to be assigned to fullnight CPAP titration, and tending to use CPAP less per night than men. A comparison
of CPAP use within the split-night sample revealed that nightly CPAP use was very
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similar for the CPAP habituation and education control participants with means o f 5.07
(SD = 2.34) and 5.26 (SD = 1.76) hours, respectively. These data were similar to the
mean nightly CPAP use o f 5.5 hours per night reported in a study by Hui et al. (2000)
that offered newly diagnosed OSAS patients extensive support during the first month
including daily, followed by weekly supportive telephone calls and that had participants
meet with their physician after the first and second week of CPAP use.
An unexpected finding was that women used CPAP significantly less per night
than men, with women using CPAP an average of 1.61 less per night. A difference of
this magnitude would be clinically meaningful; however, the comparison o f men versus
women for CPAP use is very similar to the split-night versus full-night comparison for
CPAP use, in that the vast majority of the data available for men is from split-night
participants (n = 26, 78.7%) and, conversely, the vast majority o f data available for
women is from full-night participants (n = 8, 73%). Although women and men did not
differ on the variables o f age or BMI, there was a highly significantly significant
difference (p = .005) in OSAS severity, with the men having nearly twice as many
respiratory events per hour as the women, with a mean A+HI of 51.25 (SD = 30.65) and
25.73 (SD = 12.64) respectively. Studies by Hui et al. (2001), Bennett et al. (1998),
Meurice et al. (1994), suggest that severity of OSAS might best explain the gender
difference for CPAP use. Furthermore, there was a statistically significant correlation
between gender and A+HI in the current study. Therefore, the difference in CPAP use
between men and women might be best accounted for OSAS severity. This is further
supported by the fact that there was no statistically significant difference between CPAP
use between men and women in the full-night condition with men using CPAP an
average o f 3.87 (SD = 2.30) hours per night, and women using CPAP an average of
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3.61 (SD = 2.19) hours per night (no gender comparison was made for the split-night
because there were only three female participants). Additionally, three female
participants were using CPAP for 45 minutes or less per day at follow-up, which had a
great impact on the mean for CPAP use in women. If these data points were removed,
the mean CPAP use of the remaining eight females participants would be 4.50 hours per
day, which is very similar to the mean CPAP use for the male sample of 5.08 hours per
day. Data from 33 men were compared against data from only 11 women, and if more
female participants had been included in the sample, the impact of extreme these scores
would have been attenuated.
One explanation for the lack of statistically significant findings for the CPAP
habituation procedure was generally low statistical power for the tests. Power was very
low for the MANOVAs in particular, with an observed power o f only . 14 for each
analysis. The power o f MANOVA is affected by the factors of sample size, effect size,
and the degree to which the dependent variables are correlated (Stevens, 1980). The
factors of sample size and effect size have the most bearing on the lack of significant
findings for the PSG variable data analysis. The sample size achieved in the current
study was less than proposed, which was particularly true for the full-night conditions.
The number of participants available for data analysis would have been decreased
further if STA had been included in the MANOVAs, which is why this PSG variable
was analyzed separately. Unfortunately, STA was missing for several participants due
to the loss of electronic data by clinic personnel at the SDA and HMC. Increasing the
sample size would have improved power for the split-night PSG analyses to a small
degree. The addition o f participants in the full-night groups might have improved
power to a greater degree than the addition of subjects to the split-night groups
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considering that the number per group was particularly small. Although an exact post
hoc estimate of power for the CPAP acceptance analysis was not calculated, observed
power for these tests would likely be comparable to the low power observed for the
other analyses (Fleiss, 1981). This is particularly applicable to the acceptance data for
the small number o f full-night participants. In regard to CPAP use, a large effect size
had been estimated for the CPAP habituation procedure. The outcome of the study,
particularly when examining the split-night sample, suggests that any positive effect
that the CPAP habituation procedure might have produced for CPAP use would be quite
small even if it were statistically significant. One of the primary research goals was to
not only produce a statistically significant difference in CPAP use with CPAP
habituation, but to produce a clinically meaningful improvement o f at least one hour of
CPAP use per night beyond the level of nightly CPAP use that has been reported
without such an intervention.
An examination of factors that might have negatively impacted the research
methodology requires consideration when interpreting the results of the study. One
problem that was unknown at the beginning of the study was the possibility that
participants from the SDA and the HMC would receive a benzodiazepine hypnotic
medication during CPAP. The physicians and the clinic support staff informed the
patients that if they experienced difficulty sleeping with CPAP, they would receive S
mg of zolpidem (Ambien), and that the medication could be administered a second time
if patients continued to have difficulty sleeping with CPAP. A routine physician order
for the technicians to administer 5 mg o f zolpidem to patients who were not asleep after
one hour on CPAP resulted in a large number (n = 23) of potential participants being
eliminated from the study. Sixty-one percent (n = 14) of participants who received
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zolpidem were in the education control groups. This was an uncontrolled source of
variance that could not be corrected by the investigator. The use of the hypnotic
medication was a serious potential confound, given that the purpose o f the study was to
evaluate the effectiveness of CPAP habituation in promoting adjustment to and
acceptance o f CPAP, because it would have offered a competing explanation for
adjustment to CPAP for those who received it. More importantly, it is arguable that the
participants who received the hypnotic medication would have continued to experience
difficulty in adjusting to CPAP without it, which very likely would have been reflected
in poor sleep architecture and greater difficulty accepting and using CPAP, i.e., they
might have expected to have a more negative experience with the CPAP titration trial
because of their tendency to sleep onset and/or sleep maintenance insomnia. As a
result, participants who received zolpidem were excluded from the analyses, and thus
participants who represented an important segment of the patient population and who
might have benefited most from CPAP habituation, could not be included in the current
sample. Equally important, the exclusion of participants who received zolpidem might
have had a positive impact on the results by artificially inflating the percentage of initial
acceptance o f CPAP that was observed for the complete sample.
A different segment of the population that was under-represented in the current
study was persons aged 65 and older as the vast majority of potential participants in this
age group could not be recruited from the SDA and the HMC because Medicare was
their primary insurance provider, which required them to receive their CPAP devices at
a location other than the SDA (HMC patients also received their CPAP devices at the
SDA). Only one participant from the OCBR was included from this age group, and no
follow-up data CPAP was available for this individual. This limited the ability to
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generalize the findings o f the study to persons aged 6S and older, a highly significant
population given the tendency for OSAS to occur more frequently and to be more
severe in patients as they age. The impact of the virtual exclusion o f persons aged 6S
and older is likely to be limited in view o f a study by Parish, Lyng, and Wisbey (2000),
which showed that CPAP use in persons aged 65 and older was very similar to that of
persons under age 65.
A methodological problem of the study that should be noted was the use of more
than one data collection site, which might have compromised experimental control in
terms of the research and clinical procedures. A consequence of utilizing three data
collection sites was that different clinic personnel and experimenters interacted with the
patient samples at the SDA and the HMC versus the OCBR. Data collection was
pursued at the OCBR in response to a five-month delay in beginning the data collection
at the SDA, and the unavailability o f the Sleep/Wake Disorders Center at the University
of Alabama at Birmingham as a data collection site that had been proposed originally.
Data collection was relocated from the SDA to the HMC due to a decision by the
administration to move the vast majority of potential participants to the HMC for
insurance purposes. Because the Birmingham data collection sites were under the same
management and used the same clinic personnel, data from the SDA and HMC were
combined, and compared with data from the OCBR. Comparisons of the Birmingham
vs. OCBR data collection sites between participants from the same group with Mann
Whitney U revealed statistically significant differences for SOL (U = 10.00, p = .026)
and STA (U = 6.00, p = .023) for the Hab/Ed-SN participants, and also revealed
statistically significant differences for STA ((/ = 5.00, p = .007) and SE (U = 8 50, p =
.018) for the Ed-SN participants. The observed differences suggest that there might
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have been important environmental or procedural differences between the sleep
disorders centers. As efforts were made to administer the procedures of the study and
the CPAP titration in the same manner to all of the participants, it is possible that
idiosyncratic inter-laboratory differences in the scoring of polysomnograms might
account for the differences observed in the PSG variables. However, the overall impact
o f the differences for the PSG variables between participants from the SDA and the
HMC versus the OCBR was mitigated by the fact that participants from the OCBR
represented a small proportion (16.39%, n = 10) of the sample, and that those
participants were evenly distributed between the split-night groups (Hab/Ed-SN, n = 4;
Ed-SN, n = 4) and the full-night groups (Hab/Ed-FN, n = 1; Ed-FN, n = 1) for the PSG
data analyses. It is very important to note, however, that there were no statistically
significant differences for CPAP acceptance or CPAP use between participants from the
Birmingham data collection sites and the OCBR data collection site.
Another methodological consideration was that the CPAP habituation
procedure, which consisted of only one 30-minute exposure to different CPAP
pressures, might have been inadequate to promote complete habituation to the CPAP
stimulus. Edinger and Radtke (1993) demonstrated that a gradual desensitization
procedure, which included wearing the CPAP mask with pressure for one hour per day
for five consecutive days, allowed an individual who had been unable to tolerate CPAP
to be compliant with CPAP as measured at a six-and-one-half-year follow-up. In the
context of the Edinger and Radtke (1993) study, the CPAP habituation procedure in the
current study consisted o f only a single trial and was brief, with only 30 minutes of in
vivo experience for participants. Although this case report by Edinger and Radtke
(1993) addressed desensitization as opposed to habituation, it does suggest that a series
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of habituation trials and trials of longer duration might have been beneficial. Such a
procedure appears to have merit in particular for patients who experience noteworthy
anxiety during CPAP, as anxiety has been shown to be a factor in reduced CPAP
compliance (Kribbs et al., 1993b; Nino-Murcia et al., 1989). There also is a remote
possibility that sensitization, rather than habituation, might have occurred for
participants in the Hab/Ed-FN group. However, the evidence available is contrary to a
hypothesis of sensitization in the current study. An examination o f the effect of the
CPAP habituation procedure showed that only 4 of 69 (5.7%) participants who agreed
to undergo the CPAP habituation procedure chose to end the procedure early, and
consequently were no longer eligible for the study An identical number of participants
requested to settle on the next to highest CPAP habituation pressure level of 8 cm H20
as their final habituation setting but were able to complete a 30-minute trial with CPAP.
Conversely, 61 o f 69 (88.4%) of those who agreed to undergo the CPAP procedure
experienced no difficulty tolerating the final pressure setting o f 10 cm H20, and 65 of
69 participants (94.2%) were able to complete a 30-minute trial o f CPAP habituation.
However, given that that CPAP habituation did not prove useful in the Hab/Ed-SN
group and that any possible benefits from CPAP habituation procedure would be small,
it does not appear that it would be beneficial to include more participants in the fiillnight groups. In fact, it if is the case the CPAP habituation procedure resulted in
sensitization or worse outcome in patients with milder OS AS, it would be harmful and
unethical to recruit more participants using the procedure as it is currently designed.
Finally, given that acceptance and compliance with CPAP in the current sample
of OSAS patients was comparable to what has been observed in the literature, the issue
o f what degree o f compliance is beneficial warrants discussion. It has been established
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that OS AS patients regarded as being compliant with CPAP are sleeping without
treatment for large parts of the night (Kribbs et al., 1993b, Rauscher et al. 1993; Pieters
et al. 1996). This is a very important observation because a study of new CPAP users
demonstrated that the residual benefit o f CPAP after it was removed following four
hours of sleep was very limited, resulting in a mean A+HI of 34.9 for the rest of the
night without CPAP (Hers et al., 1997). Similar results were obtained in a study of
persistent CPAP users (average treatment duration o f 8.43 months) that examined sleep
after removal o f CPAP following the first four hours of sleep, which again, showed that
patients experienced unequivocal sleep apnea (mean A+HI = 28.7) for the remainder to
the night (Rauscher, Popp, Wanke, & Zwick, 1991a). However, there also is some
evidence to suggest that less than optimal use of CPAP may yield some benefits. A
study by Engleman et al. (1994) showed statistically significant improvement in OS AS
patients on the MSLT, OSAS symptom ratings, mood, and cognitive performance with
objectively monitored CPAP use that averaged only 3.4 hours per night after a fourweek follow-up. However, it should be noted that the mean MSLT value of 7.2 minutes
to sleep onset remained in a range that is considered indicative of moderate to severe
daytime sleepiness, and the other observed improvements were small.
In summary, the CPAP habituation procedure was not demonstrated to add any
benefit to CPAP education in an examination of sleep quality during CPAP, acceptance
o f CPAP, and nightly use of CPAP There were no significant differences between the
CPAP habituation/education treatment groups and education control groups on any of
the variables examined. Approximately 80% o f the participants agreed to a trial of
CPAP treatment at home, which was comparable to initial acceptance rates for CPAP in
the treatment compliance literature. The average nightly CPAP use for the complete
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sample was 4.68 hours, which was also comparable with average nightly use o f CPAP
that has been reported in the CPAP compliance literature. Men were found to use
CPAP significantly more per night than women, but this difference is most likely
accounted for by severity o f OSAS as men had twice as many respiratory events per
hour than women. There were several factors that might have influenced the results of
the study, most notable of which were the exclusion of potential participants who had
difficulty adjusting to CPAP and received a hypnotic medication during CPAP, and the
exclusion o f patients aged 65 and older because of insurance coverage considerations.
Additionally, a low statistical power was observed, which limited the ability to detect
statistically significant differences.
The goal of the present study was to address a gap in the CPAP compliance
literature regarding the importance of the manner in which OSAS patients are
introduced to CPAP therapy and its effect on acceptance and compliance. The CPAP
habituation procedure was designed in response to problems that had been reported in
the CPAP compliance literature including poor sleep with CPAP and the experience of
anxiety in some OSAS patients who were non-compliant with CPAP treatment. Future
research with CPAP compliance could address a number of issues. Interventions might
be tailored to the needs of more specific OSAS patient populations For persons with
milder OSAS, a greater emphasis on education such as that reported by Likar et al.,
(1997), which includes continuing education throughout treatment and that emphasizes
the progressive nature o f OSAS might be useful for long-term compliance with CPAP.
Replication o f the findings o f Edinger and Radtke (1993) in a small series of patients
would lend much greater support for use o f their method of CPAP desensitization in
persons who experience significant anxiety during CPAP. Finally, although it appeared
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that severity o f OSAS accounted for an observed gender difference in nightly CPAP
use, research specifically addressing possible gender differences for CPAP compliance
is lacking. More women are being diagnosed with OSAS and a recent study by
O’Connor, Thomley, and Hanley (2000) found that the ratio o f men to women for mild
OSAS (classified as an A+HI of 5 to 25) was 2.2 to 1 and was 3.2 to 1 for all OSAS
patients in their sample. O’Connor et al. (2000) also noted that 62% of women in their
sample experienced the majority of the OSAS in REM sleep as compared to 24% of
men. Such a difference suggests that it would be worthwhile to conduct research
focusing on possible gender differences for CPAP compliance. Given that OSAS has
been shown to be associated with ischemic heart disease (Hung, Whitford, Parsons, &
Hillman, 1990) and increased mortality (Partinen, Jamieson, & Guilleminault, 1988)
and that CPAP is clearly the treatment of choice for OSAS, the search for means to
increase CPAP compliance should be continued.

70

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

References
Agnew, H. W , Jr., Webb, W B., & Williams, R. L. (1966). The first night
effect: An EEG study of sleep. Psychophysiology, 2, 263-266.
Aldrich, M. S. (1994). Cardinal manifestations of sleep disorders. In M. H.
Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice o f sleep medicine (2nd
ed.; pp. 413-425). Philadelphia: W.B. Saunders Company.
American Psychological Association (1992). Ethical principles of psychologists
and code of conduct. American Psychologist, 47, 1597-1611.
American Sleep Disorders Association (1992). EEG arousals: Scoring rules and
examples. Sleep, 15, 173-184.
American Sleep Disorders Association (1997). The international classification
o f sleep disorders: Diagnostic and coding manual (Rev. ed.). Rochester, MN: Davies
Printing Company.
American Thoracic Society (1994). Indications and standards for use of nasal
continuous positive airway pressure (CPAP) in sleep apnea syndromes. American
Journal o f Respiratory and Critical Care Medicine, ISO, 1738-1745.
Anch, A. M., Remmers, J. E., & Bunce, H. (1982). Supraglottic airway
resistance in normal subjects and patients with occlusive sleep apnea. Journal o f
Applied Physiology, 53, 1158-1163.
Bedard, M., Montplaisir, J , Malo, J., Richer, F., & Rouleau, I. (1993). Persistent
neuropsychological deficits and vigilance impairment in sleep apnea syndrome after
treatment with continuous positive airways pressure (CPAP). Journal o f Clinical and
Experimental Neuropsychology, 15, 330-341.
Bedard, M., Montplaisir, J., Richer, F., & Malo, J. (1991). Nocturnal hypoxemia
as a determinant o f vigilance impairment in sleep apnea syndrome. Chest, 100, 367-370.
Bennett, L. S., Langford, B. A., Stradling, J. R., & Davies, R J. O. (1998). Sleep
fragmentation indices as predictors of daytime sleepiness and nCPAP response in
obstructive sleep apnea. American Journal o f Respiratory and Critical Care Medicine,
158, 778-786.
Berthon-Jones, M., & Sullivan, C. E. (1987). Time course o f change of
ventilatory response to C 02 with long term CPAP therapy for obstructive sleep apnea.
American Review o f Respiratory Disease, 135, 144-147.
Berthon-Jones, M., Lawrence, S., Sullivan, C. E., & Grunstein, R. (1996). Nasal
continuous positive airway pressure treatment: Current realities and future. Sleep, 19,
S131-S135.
71

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Bonnet, M.H. (1985). Effect of sleep disruption on sleep, performance, and
mood. Sleep, 8, 11-19.
Bonnet, M.H. (1986). Performance and sleepiness as a function of frequency
and placement o f sleep disruptioa Psychophysiology, 23, 263-271.
Bonnet, M.H. (1987). Sleep restoration as a function of periodic awakening,
movement, or electroencephalographic change. Sleep, 10, 364-373.
Carskadon, M.A., Brown, E. D., & Dement, W. C. (1982). Sleep fragmentation
in the elderly: Relationship to daytime sleep tendency. Neurobiology o f Aging, 3, 321327.
Carskadon, M.A., & Dement, W. C. (1977). Sleep tendency: An objective
measure o f sleep loss. Sleep Research, 6, 200.
Cartwright, R. D. (1984). Effects of sleep position on sleep apnea severity.
Sleep, 7, 110-114.
Cartwright, R. D., & Samelson, C. F. (1982). The effects of a nonsurgical
treatment for obstructive sleep apnea syndrome: The tongue-retaining device. Journal
o f the American M edical Association, 248, 705-709.
Chervin, R. D., Theut, S., Bassetti, C., & Aldrich, M. S. (1997). Compliance
with nasal CPAP can be improved by simple interventions. Sleep, 20, 284-289.
Collard, P., Pieters, T., Aubert, G., Delguste, P., & Rodenstein, D. O. (1997).
Compliance with nasal CPAP in obstructive sleep apnea patients. Sleep Medicine
Reviews, I, 33-44.
De Berry-Borowiecki, B., Kukwa, A., & Blanks, R. H. I. (1985). Indications for
uvulopalatopharyngoplasty surgery for snoring and obstructive sleep apnea. Archives o f
Otolaryngology, III, 659-663.
De Berry-Borowiecki, B., Kukwa, A., Blanks, R. H. I., & Irvine, C. A. (1988).
Cephalometric analysis for diagnosis and treatment of obstructive sleep apnea.
Laryngoscope, 98, 226-234.
Domjan, M. (19%). The essentials o f conditioning and learning. Pacific Grove,
CA: Brooks/Cole Publishing Company.
Douglas, N. J. (1994). Control of ventilation during sleep. In M. H. Kryger, T.
Roth, & W. C. Dement (Eds.), Principles and practice o f sleep medicine (2nd ed.; pp.
204-211). Philadelphia: W.B. Saunders Company.
Downey, R., & Bonnet, M. H. (1987). Performance during frequent sleep
disruption. Sleep, 10, 354-363.
72

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Edinger, J. D , & Radtke, R. A. (1993). Use of in vivo desensitization to treat a
patient’s claustrophobic response to nasal CPAP. Sleep, 16, 678-680.
Engleman, H. M., Asgari-Jirhandeh, N., McLeod, A. L., Ramsay, C. F., Deary,
I. J., & Douglas, N. J. (1996). Self-reported use of CPAP and benefits of CPAP
therapy. Chest, 109, 1470-76.
Engleman, H. M., Martin, S. E., & Douglas, N. J. (1994). Compliance with
CPAP therapy in patients with the sleep apnoea/hypopnoea syndrome. Thorax, 49, 263266.
Ferguson, K. A., Ono, T., Lowe, A. A., Keenan, S. P., & Fleetham, J. A.
(1996). A randomized, crossover study o f an oral appliance vs nasal-continuous positive
airway pressure in the treatment o f mild-moderate obstructive sleep apnea. Chest, 109,
1296-1275.
Fleiss, J. L. (1981). Statistical methodsfo r rates and proportions (2nd ed). New
York: John Wiley & Sons
Fletcher, E. C. (1996). Can the treatment of sleep apnea syndrome prevent the
cardiovascular consequences? Sleep, 19, S67-S70.
Fletcher, E., & Luckett, R. A. (1991). The effect of positive reinforcement on
hourly compliance in nasal continuous positive airway pressure users with obstructive
sleep. American Review o f Respiratory Disease, 143, 936-941.
Fleury, B., Rakotonanahary, D , Tehindrazanarivelo, A D , Hausser-Hauw, C ,
& Lebeau, B. (1994). Long-term compliance to continuous positive airway pressure
therapy (nCPAP) set up during a split-night polysomnography. Sleep, 17, 512-515.
Frith, R W., & Cant, B. R. (1985). Severe obstructive sleep apnea treated with
long term nasal continuous positive airway pressure. Thorax, 40, 45-50.
George, C. F., Millar, T. W., Kryger, M. H. (1988). Sleep apnea and body
position during sleep. Sleep, 11, 90-99.
Greenberg, G. D., Watson, R. K., & Deptula, D. (1987). Neuropsychological
dysfunction in sleep apnea. Sleep, 10, 254-262.
Groves, P. M., & Thompson, R. F. (1970). Habituation. A dual-process theory.
Psychological Review, 77, 419-450.
Guilleminault, C. (1982). Sleep and breathing. In C. Guilleminault (ed ),
Sleeping and waking disorders: Indications and techniques (pp. 155-182). Menlo Park,
CA: Addison-Wesley.

73

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Guilleminault, C. (1994). Clinical features and evaluation of obstructive sleep
apnea syndrome. In M. H. Kryger, T. Roth, & W. C. Dement (Eds ), Principles and
practice o f sleep medicine (2n ed., pp. 667-677). Philadelphia: W.B. Saunders
Company.
Haponik, E. F., Smith, P. L., Bohlman, M. E., Allen, R. P., Goldman, S. M., &
Bleecker, E. R. (1983). Computerized tomography in obstructive sleep apnea. American
Review o f Respiratory Disease, 127, 221-226.
Harper, R. M., & Sauerland, E. K. (1978). The role o f the tongue in sleep apnea.
In C. Guilleminault and W. C. Dement (Eds.), Sleep Apnea Syndromes (pp. 219-234).
New York: Alan R. Liss.
He, J., Kryger, M. H., Zorick, F. J., Conway, W., & Roth, T. (1988). Mortality
and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest, 94,
9-14.
Hers, V., Liistro, G., Dury, M., Collard, P., Aubert, G., & Rodenstein, D 0.
(1997). Residual effect o f nCPAP applied for part of the night in patients with
obstructive sleep apnoea. European Respiratory Journal, 10, 973-976.
Hinkle, D.E., Wiersma, W., & Jurs, S.G. (1994). Applied statistics fo r the
behavioral sciences. Boston: Houghton Mifflin Company.
Hoffstein, V., Viner, S., Mateika, S., & Conway, J. (1992). Treatment of
obstructive sleep apnea with nasal Continuous Positive Airway Pressure. American
Review o f Respiratory Disease, 145, 841-845.
Hui, D. S., Chan, J. K. W , Choy, D. K. L„ Ko, F W S., Li, T S. T , Leung, R.
C. C., et al. (2000) Effects of augmented continuous positive airway pressure education
and support on compliance and outcome in a Chinese population. Chest, 117, 14101416.
Hui, D. S., Choy, D K. L„ Li, T. S. T , Ko, F W. S., Wong, K. K., Chan, J K.
W , et al. (2001). Determinants of continuous positive airway pressure compliance in a
group of Chinese patients with obstructive sleep apnea. Chest, 120, 170-176.
Hung, J., Whitford, E.G., Parsons, R. W., & Hillman, D. R. (1990). Association
of sleep apnoea with myocardial infarction in men. Lancet, 336, 261-264.
Issa, F. G., & Sullivan, C. E. (1982). Alcohol, snoring, and sleep apnea. Journal
o f Neurology, Neurosurgery, and Psychiatry, 45, 353-359.
Issa, F. G., & Sullivan, C. E. (1984). Upper airway closing pressures in
obstructive apena. Journal o f Applied Physiology, 57, 520-527.

74

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Isono, S., & Remmers, J. E. (1994). Anatomy and physiology o f upper airway
obstruction. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice
o f sleep medicine (2nd ed.; pp. 642-656). Philadelphia: W.B. Saunders Company.
Jamieson, A., Guilleminault, C., Partinen, M., & Quera-Salva, M. A. (1986).
Obstructive sleep apneic patients have craniomandibular abnormalities. Sleep, 9, 469477.
Kribbs, N.B. (1997). Methods and problems of treatment compliance in
obstructive sleep apnea. In M. R. Pressman & W. C. Orr (Eds ), Understanding sleep:
The evaluation and treatment o f sleep disorders (pp. 299-313). Washington, DC:
American Psychological Association.
Kribbs, N.B., Pack, A. I., Kline, L.R., Getsy, J.E., Schuett, J.S., Henry, J.N., et
al. (1993a). Effects o f one night without nasal CPAP treatment on sleep and sleepiness
in patients with obstructive sleep apnea. American Review o f Respiratory Disease, 147,
1162-1168.
Kribbs, N.B., Pack, A. I., Kline, L. R., Smith, P. L., Schwartz, A. R., Schubert,
N M , et al. (1993b). Objective measurement of patterns of nasal CPAP use by patients
with obstructive sleep apnea. American Review o f Respiratory Disorders, 147, 887-895.
Krieger, J., & Kurtz, D. (1988). Objective measurement of compliance with
nasal CPAP treatment for obstructive sleep apnoea syndrome. European Respiratory
Journal, I. 436-438.
Kripke, D. F., & Ancoli-Israel, S. (1983). Epidemiology of sleep apnea among
the aged: Is sleep apnea a fatal disorder? In C. Guilleminault & E. Lugaresi (Eds.),
Sleep/Wake Disorders: Natural History, Epidemiology, and Long-term Evolution (pp.
137-142). New York: Raven Press.
Likar, L. L., Panciera, T. M., Erickson, A. D., & Rounds, S. (1997). Group
education sessions and compliance with nasal CPAP therapy. Chest, III, 1273-1277.
Lojander, J., Maasilta, P., Partinen, M., Brander, P. E., Salmi, T., & Lehtonen,
H. (1996). Nasal-CPAP, surgery, and conservative management for treatment of
obstructive sleep apnea syndrome. Chest, 110, 114-119.
Lowe, A. A (1994). Dental appliances for the treatment o f snoring and
obstructive sleep apnea, hi M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles
and practice o f sleep medicine (2nd ed.; pp. 722-735). Philadelphia: W.B. Saunders
Company.
Lowe, A. A., Gionhaku, N., Takeuchi, K., & Fleetcham, J. A. (1986). Threedimensional reconstructions o f tongue and airway in adult subjects with obstructive
sleep apnea. American Journal o f Orthodontics and Dentofacial Orthopedics, 90, 364374.
75

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Lyberg, T., Krogstad, O , & Djupesland, G. (1989). Cephalometric analysis in
patients with obstructive sleep apnea syndrome. Q. Soft tissue morphology. Journal o f
Laryngology and Otolaryngology, 103, 293-297.
Magee, J., Harsh, J., & Badia, P. (1987). Effects of experimentally-induced
sleep fragmentation on sleep and sleepiness. Psychophysiology, 24, 528-534.
McCarthy, M. E., & Waters, W. F. (1997). Decreased attentional responsivity
during sleep deprivation: Orienting response latency, amplitude, and habituation. Sleep,
20, 115-123.
Meurice, J., Dore, P., Paquereau, J., Neau, J., Ingrand, P., Chavagnat, J., et al.
(1994). Predictive factors o f long-term compliance with nasal continuous positive
airway pressure treatment in sleep apnea syndrome. Chest, 105, 429-433.
Meurice, J. C., Paquereau, J., Neau, J. P., Caron, F., Dore, P., Ingrand, P., et al.
(1997). Long-term evolution of daytime somnolence in patients with sleep
apnea/hypopnea syndrome treated by continuous positive airway pressure. Sleep, 20,
1162-1166.
Mickelson, S. A. (1996). Laser-assisted uvulopalatoplasty for obstructive sleep
apnea. Laryngoscope, 106, 10-13.
Nino-Murcia, G., McCann, C. C., Bliwise, D. L., Guilleminault, C., & Dement,
W. C. (1989). Compliance and side effects in sleep apnea patients treated with nasal
continuous positive airway pressure. Western Journal o f Medicine, 150, 165-169.
O’Connor, C., Thomley, K.S., & Hanly, P. J. (2000). Gender differences in
polysomnographic features of obstructive sleep apnea. American Journal o f Respiratory
ami Critical Care Medicine, 161, 1465-1472.
Orr, W. C. (1997). Obstructive sleep apnea: Natural history and varieties of the
clinical presentation. In M. R. Pressman & W. C. Orr (Eds ), Understanding sleep: The
evaluation and treatment o f sleep disorders (pp. 267-281). Washington, DC: American
Psychological Association.
Parish, J. M., Lyng, P. J., & Wisbey, J. (2000). Compliance with CPAP in
elderly patients with OSA. Sleep Medicine, I, 209-214.
Partinen, M. (1994). Epidemiology of sleep disorders. In M. H. Kryger, T. Roth,
& W. C. Dement (Eds), Principles and practice o f sleep medicine (2nd ed., pp. 437452). Philadelphia: W.B. Saunders Company.
Partinen, M., Guilleminault, C., Quera-Salva, M .A, & Jamieson, A (1988).
Obstructive sleep apnea and cephalometric roentgenograms. Chest, 93, 1199-1205.
Partinen, M., Jamieson, A., & Guilleminault, C. (1988). Long-term outcome for
obstructive sleep apnea syndrome patients. Chest, 94, 1200-1204.
76

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Pepin, J. L., Ferretti, G., Veale, D., Romand, P., Coulomb, M., Brambilla, C., et
al. (1992). Somnofluoroscopy, computerized tomography and cephalometry in the
assessment o f the airway in obstructive sleep apnoea. Thorax, 47, ISO-6.
Pepin, J. L., Levy, P., Veale, D. & Ferretti, G. (1992). Evaluation of the upper
airway in sleep apnea syndrome. Sleep 15, S50-S55.
Petrinovich, L. (1984). A two-factor dual-process theory of habituation and
sensitization. In H. V. S. Peeke & L. Petrinovich (Eds ), Habituation, sensitization, and
behavior (pp. 17-55). Orlando, FL: Academic Press, Inc.
Philip, P., Stoohs, R., & Guilleminault, C. (1994). Sleep fragmentation in
normals: A model for sleepiness associated with upper airway resistance syndrome.
Sleep, 17, 242-247.
Pieters, T., Collard, P., Aubert, G., Dury, M., Delguste, P., & Rodenstein, D. O.
(1996). Acceptance and long-term compliance with nCPAP in patients with obstructive
sleep apnoea syndrome. European Respiratory Journal, 9, 939-944.
Pribitkin, E. A., Schutte, S. L., Keane, W. M., Mao, V., Cater, J. R., Doghramji,
K , et al. (1998). Efficacy o f laser-assisted uvulopalatoplasty in obstructive sleep apnea.
Otolaryngology: Head and Neck Surgery, 119, 643-647.
Rajagopal, K.R., Bennett, L.L., Dillard, T.A., Tellis, C. J., & Tenholder, M. F.
(1986). Overnight nasal CPAP improves hypersomnolence in sleep apnea. Chest, 90,
172-176.
Rauscher, H., Formanek, D., Popp, W., & Zwick, H. (1993). Self-reported vs
measured compliance with nasal CPAP for obstructive sleep apnea. Chest, 103, 16751680.
Rauscher, H., Popp, W., Wanke, T., & Zwick, H. (1991a). Breathing during
sleep in patients treated for obstructive sleep apnea: Nasal CPAP for only part of the
night. Chest, 100, 156-159.
Rauscher, H., Popp, W., Wanke, T., & Zwick, H. (1991b). Acceptance of CPAP
for sleep apnea. Chest, 100, 1019-1023.
Rechtschaffen, A., & Kales, A. (1968). A manual o f standardized terminology,
techniques, and scoring system fo r sleep stages o f human subjects. Publication No.
204. Washington, DC: National Institutes of Health.
Reeves-Hoche, M. K., Meek, R., & Zwillich, C. W. (1994). Nasal CPAP: An
objective evaluation o f patient compliance. American Journal o f Respiratory and
Critical Care Medicine, 149, 149-154.

77

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Rodenstein, D. O. (1992). Assessment o f uvulopalatopharyngoplasty for the
treatment o f sleep apnea syndrome. Sleep, 15, SS6-S62.
Roehrs, T., Merlotti, L., Petrucelli, N., Stepanski, E., & Roth, T. (1994).
Experimental sleep fragmentation. Sleep, 17, 438-443.
Roehrs, T., Zorick, F., Wittig, R., Conway, W., & Roth, T. (1989). Predictors of
objective level o f daytime sleepiness in patients with sleep-related breathing disorders.
Chest, 95, 1202-1206.
Rolfe, I., Olson, L. G., & Saunders, N. A. (1991). Long-term acceptance of
continuous positive airway pressure in obstructive sleep apnea. American Review o f
Respiratory Disease, 144, 1130-1133.
Roth, T., Hartse, K. M., Zorick, F., & Conway, W. (1980). Multiple naps and
the evaluation o f daytime sleepiness in patients with upper airway sleep apnea. Sleep, 3,
425-439.
Roth, T., Roehrs, T., & Zorick, F. (1982). Sleepiness: Its measurement and
determinants. Sleep, 5, S128-S134.
Ryan, C. F., Lowe, A. A., Li, D., & Fleetham, J. A. (1991). Magnetic resonance
imaging o f the upper airway in obstructive sleep apnea before and after chronic nasal
continuous positive airway pressure therapy. American Review o f Respiratory Disease,
144, 939-944.
Sanders, M. H. (1994). Medical therapy for sleep apnea. In M. H. Kryger, T.
Roth, & W. C. Dement (Eds.), Principles and practice o f sleep medicine (2nd ed.; pp.
678-693). Philadelphia: W.B. Saunders Company.
Sanders, M. H., Gruendl, C. A., & Rogers, R. M. (1986). Patient compliance
with nasal CPAP therapy for sleep apnea. Chest, 90, 330-333.
Sanders, M. H., & Kern, N. (1992). Obstructive sleep apnea treated by
independently adjusted inspiratory and expiratory positive airway pressures via nasal
mask: Physiologic and clinical implications. Chest, 98, 317-324.
Saskin, P. (1997). Obstructive sleep apnea: Treatment options, efficacy, and
effects. In M. R. Pressman & W. C. Orr (Eds ), Understanding sleep: The evaluation
and treatment o f sleep disorders (pp. 283-297). Washington, DC: American
Psychological Association.
Scrima, L., Broudy, M., Nay, K., & Cohn, M. A. (1982). Increased severity of
obstructive sleep apnea after bedtime alcohol ingestion. Diagnostic potential and
proposed mechanism o f actions. Sleep, 5, 318-328.

78

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Shepard, J.W. (1994). Cardiorespiratory changes in obstructive sleep apnea. In
M. H. Kryger, T. Roth, & W. C. Dement (Eds), Principles and practice o f sleep
medicine (2nd ed.; pp. 657-666). Philadelphia: W.B. Saunders Company.
Shepard, J.W., Stanson, A. W., Sheedy, P. F., & Westbrook, P. R. (1990). In F.
G. Issa, P. M. Suratt, & J. E. Remmers (Eds.), Sleep and respiration.(pp. 273-282). New
York: WUey-Liss.
Simmons, F. B., Guilleminault, C., & Miles, L. (1984). The
palatopharyngopiasty operation for snoring and sleep apnea. An interim report.
Otolaryngology: Head, and Neck Surgery, 92, 375-380.
Smith, P. L., Gold, A. R., Meyers, D. A., Haponik, E. F., & Bleecker, E. R.
(1985). Weight loss in mildly to moderately obese patients with obstructive sleep apnea.
Annals o f Internal Medicine, 103,850-855.
Stepanski, E., Lamphere, J., Badia, P., Zorick, F., & Roth, T. (1984). Sleep
fragmentation and daytime sleepiness. Sleep, 7, 18-26.
Stevens, J.P. (1980). Power of the multivariate analysis of variance tests.
Psychological Bulletin, 88, 728-737.
Strollo, P. J., Sanders, M. H., Costantino, J. P., Walsh, S. K., Stiller, R A., &
Atwood, C. W. (1996). Split-night studies for the diagnosis and treatment of sleepdisordered breathing. Sleep, 19, S255-S259.
Sullivan, C. E., Berthon-Jones, M., Issa, F. G., & Eves, L. (1981). Reversal of
obstructive sleep apnea by continuous positive airway pressure applied through the
nares. Lancet, I, 862-865.
Sullivan, C. E , & Grunstein, R. R. (1994). Continuous positive airway pressure
in sleep-disordered breathing. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.),
Principles and practice o f sleep medicine (2nd ed.; pp. 694-705). Philadelphia: W.B.
Saunders Company.
Taasan, V, Block, A. J,Boysen, Wynne, J. W., White, C., & Lindsey, S. (1981).
Alcohol increases sleep apnea and oxygen desaturation in asymptomatic men. American
Journal o f Medicine, 71, 240-245.
Telakivi, T., Kajaste, S., Partinen, M., Koskenvuo, M., Salmi, T., & Kaprio, J.
(1988). Cognitive function in middle-aged snorers and controls: Role o f excessive
daytime somnolence and sleep-related hypoxic events. Sleep, 11, 454-462.
Waldhom, R. E., Herrick, T. W., Nguyen, M. C., O’Donnell, A. E., Sodero, J.,
& Potolicchio, S. J. (1990). Long-term compliance with nasal continuous positive
airway pressure therapy o f obstructive sleep apnea. Chest, 97, 33-38.

79

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Walker, R P., Grigg-Damberger, M. M., & Gopalsami, C. (1999). Laserassisted uvulopalatoplasty for the treatment of mild, moderate, and severe obstructive
sleep apnea. Laryngoscope, 109, 79-8S.
Walsh, J. K., & Lindblom, S. S. (1997). Psychophysiology o f sleep deprivation
and disruption. In M. R. Pressman & W. C. Orr (Eds ), Understanding sleep: The
evaluation and treatment o f sleep disorders (pp. 73-110). Washington, DC: American
Psychological Association.
White, D. P. (1994). Central sleep apnea. In M. H. fryger, T. Roth, & W. C.
Dement (Eds.), Principles and practice o f sleep medicine (2 ed.; pp. 630-641).
Philadelphia: W.B. Saunders Company.
Young, T., Palta, M., Dempsey, J., Skatrud, J., Weber, S., & Badr, S. (1993).
Occurrence of sleep disordered breathing among middle-aged adults. New England
Journal o f Medicine, 328, 1230-1235.

80

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Appendix A
Standardized CPAP Education
What is nasal continuous positive airwav pressure and how does it work?
Nasal continuous positive airway pressure or CPAP delivers a continuous stream of
pressured air through your nose that prevents your airway from collapsing during sleep.
It is a safe and extremely effective treatment for sleep apnea, which has been in use for
almost 20 years.
Health benefits o f CPAP therapy for sleep apnea syndrome.
There are several important reasons that guided your doctor to order a sleep study with
CPAP for you. An immediate positive consequence of using CPAP is that many
persons notice a significant decrease in sleepiness, which is accompanied by increased
feelings of energy and wellbeing. A more long-term, and possibly more important
consequence o f using CPAP is decreased risk for serious medical problems, which
might be caused by untreated sleep apnea. Such problems include hypertension, heart
and lung problems, and stroke. Persons with untreated sleep apnea have also been
shown to have a higher incidence o f serious automobile and work accidents resulting
from irresistible urges to sleep. Even if you do not experience excessive sleepiness, the
regular use of CPAP every time you sleep for the whole time you are asleep is very
important in protecting you from the other problems that untreated sleep apnea might
cause. Finally, research has shown that even one night of sleep without CPAP results in
a return to how persons with sleep apnea were feeling and functioning before they
began using CPAP to treat their sleep apnea.
What to do if there are problems with vour CPAP therapy.
CPAP therapy works best when it is used every time you sleep for the entire time that
you are in bed. If you experience any problems with CPAP, which are causing you to
not use your machine or to use it less than all night, every night, call your home
healthcare company representative at (20S) S99-1020 for Alabama residents or (225)
767-1403 for Louisiana residents. Many problems with CPAP can be eliminated or
reduced.
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Appendix B
Consent Form for Participation in CPAP Adaptation, Form A
EXPERIMENTAL GROUP
1. Study Title:

Examination of a Method for Increasing Adjustment to and
Compliance with Nasal Continuous Positive Airway Pressure
(CPAP) in Persons with Obstructive Sleep Apnea Syndrome.

2. Performance Sites: Sleep Disorders Center of Alabama, Inc. and HealthSouth
Medical Center Sleep Disorders Center
3. Investigators:

Principal Investigator: Jack A. Johnson, Jr., MA. Mr. Johnson
can be reached at (205) 982-9437 from 5:30 p.m. to 7:30 p.m.
Sub-Investigator. G. Vernon Pegram, Ph D. Dr. Pegram can be
reached at (205) 599-1020 or (205) 934-7110 from 8 a.m. to 5
p.m.

4. Purpose of the Study:

5. Subject Inclusion:

To examine a method that may help patients to adjust
better to nasal Continuous Positive Airway Pressure
(called CPAP) treatment for sleep apnea.

Any person age 19 or older who has been referred by his or her
physician for a sleep study with CPAP (or with CPAP if
indicated) is eligible for participation in this study. Only eligible
persons have been invited to participate. Persons who have had a
severe head or spinal injury that resulted in leakage of
cerebrospinal fluid (the fluid that surrounds and cushions the
brain) are not eligible to participate.

6. Number o f Subjects: 92 Total People will participate in the experiment.
7. Study Procedures: All research subjects will be spending the night in the sleep
laboratory for a diagnostic evaluation, which might include a
CPAP trial aimed at finding a proper level of treatment (air
pressure) for obstructive sleep apnea, a routine procedure for
persons who have this sleep disorder. Some persons may not
receive a CPAP trial during the course of the sleep study if they
do not have obstructive sleep apnea or if the degree o f their
illness does not clinically require CPAP treatment. The
diagnostic sleep study will occur immediately following each
subject’s participation in the research study. CPAP delivers a
constant stream of pressurized air through your nose, which
prevents you from stopping breathing during sleep. There will be
no change in the way that CPAP is normally used in the Sleep
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Disorders Center o f Alabama, Inc. or the HealthSouth Medical
Center Sleep Disorders Center (depending on which sleep
laboratory you are having your examination) with the only
difference being that you will wear the CPAP mask with air
pressure before bedtime while you are not in bed and not
attempting to fall asleep. The total time that you will wear the
CPAP mask with pressure is approximately 30 minutes, during
which time you will experience a range of gradually building
CPAP pressures that is commonly experienced by persons during
the course of a sleep study with CPAP. You will be started on
the lowest pressure setting that is normally used, and the pressure
will be increased in steps until it reaches the average pressure
setting that is most commonly required to prevent sleep apnea.
You will experience each of the four pressure settings for exactly
seven and a half minutes each. The pressure will be increased
every seven and a half minutes and will increase a total o f three
times before the experiment is finished. During the time you are
wearing the CPAP mask, you may engage in any relaxing activity
that you choose including watching television or reading. Data
from your sleep study and home CPAP use (if you are prescribed
CPAP) will be compared against persons receiving the routine
laboratory procedures. All persons will receive written
information. Your participation will not reduce or modify
information that is normally gathered during the course of a sleep
study. Finally, the proposed study is not an experimental
procedure, but rather is a variation of the CPAP procedure, which
has been designed, with the aim of making adjustment to CPAP
easier.
8. Benefits:

This study may benefit you in your adjustment to CPAP and will
further scientific knowledge in the field of sleep medicine
concerning the treatment of obstructive sleep apnea syndrome.

9. Risks/Discomforts: One risk is that some persons report experiencing anxiety, which
may take the form claustrophobia, why wearing the CPAP mask.
In general, there is only one major reason that CPAP should not
be used for the treatment of sleep apnea. CPAP should not be
used with persons who have suffered a very severe head or spinal
injury that caused leakage o f cerebrospinal fluid (the fluid which
surrounds and cushions the brain). As mentioned above, persons
who have had an injury of this nature are not eligible to
participate.
10. Right to Refuse:

You have the right to end your participation in this research study
at any point that you choose and for any reason that you might
have without penalty to yourself. Choosing to drop out o f the
study will not affect the treatment that you will receive during
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your sleep study tonight or at any other time regarding your sleep
apnea.
11. Privacy:

The results of this study may be published in a research paper,
but your identity or the fact that you have participated in this
study will never be made available to public or any other agency.
Your participation in this research study will be kept confidential.
However, during the study, representatives from the US Food and
Drug Administration (FDA) will be allowed to review your
medical records that relate to the study. The Baptist Health
System Human Research Review Board may also review these
records. The records will identify you only by your initials and
an assigned research study number, not by your name.
When you sign the consent document, you are giving your doctor
permission to release your research study medical records for
review. The representatives described in the paragraph above
will use these records only to carry out their obligations
associated with this study. Every effort will be made to ensure
that your study records are not used for any other purpose, or
given to anyone else, except when required by law.

12. Financial Information:

You will not be paid to participate in this study, and there
will be no cost to you for participating.
The Baptist Health System Inc, Sleep Disorder Center of
Alabama, and Mr. Jack Johnson have made no provision
for monetary compensation in the event o f physical illness
and/or injury resulting from this research study. In the
event of such injury, medical treatment is available but is
not free o f charge. There is no monetary (or other) form
of compensation for my participation in this study.
If you have any questions about compensation or medical
treatment for research-related injuries, contact G. Vernon
Pegram, Ph.D. or Mr. Jack Johnson at the Sleep Disorder
Center of Alabama at 599-1020.

13. Alternatives:

Currently, CPAP is the best treatment for sleep apnea
for most persons. Your doctor is available to discuss other
treatment options with you. The current study is not a treatment,
but rather an examination of a way o f helping people adjust to a
treatment that they might be prescribed by their doctors after they
experience CPAP in the laboratory during sleep.
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14. Unforeseeable Risks:

There are no potential risks that a person might suffer
from resulting participation in this study.

15. Injury/Illness:

If you have questions about this study or you experience any
unexpected adverse event (side effect) while you are participating
in this study, G. Vernon Pegram, Ph.D. or Mr. Jack Johnson
should be contacted at (205) 599-1020 or (205) 934-7110. He
will be available to answer your questions before, during, and
after the study.

16. New Findings:

If any significant new findings occur during the course o f the
study including problems that others who have participated have
experienced in the study, you will be informed o f this by one of
the investigators listed above.

17. How to Learn More About Your Rights as a Reseach Subject:
If you have any questions about your rights as a research subject,
contact the Baptist Health System Human Research Review
Board, 800 Montclair Road, Birmingham, AL 35213, telephone
205/592-5700.
18. Signatures:

The study has been discussed with me and all my questions have
been answered. I may direct additional questions regarding study
specifics to the investigators. I agree to participate in the study
described above and acknowledge the investigator’s obligation to
provide me with a signed copy of the consent form.

Subject Signature

Date
The study subject has indicated to me that he/she is unable to
read. I certify that I have read this consent form to the subject
and explained that by completing the signature line above, the
subject has agreed to participate.

Signature o f Reader

Date
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Appendix C
Consent Form Tor Participation in CPAP Adaptation, Form B
CONTROL GROUP
1. Study Title:

Examination of a Method for Increasing Adjustment to and
Compliance with Nasal Continuous Positive Airway Pressure
(CPAP) in Persons with Obstructive Sleep Apnea Syndrome.

2. Performance Sites: Sleep Disorders Center of Alabama, Inc. and HealthSouth
Medical Center Sleep Disorders Center
3. Investigators:

Principal Investigator: Jack A. Johnson, Jr., MA. Mr. Johnson
can be reached at (205) 982-9437 from 5:30 p.m. to 7:30 p.m.
Sub-Investigator: G. Vemon Pegram, Ph.D. Dr. Pegram can be
reached at (205) 599-1020 or (205) 934-7110 from 8 a m. to 5
p.m.

4. Purpose o f the Study:

5. Subject Inclusion:

To examine a method that may help patients to adjust
better to nasal Continuous Positive Airway Pressure
(called CPAP) treatment for sleep apnea.

Any person age 19 or older who has been referred by his or her
physician for a sleep study with CPAP (or with CPAP if
indicated) is eligible for participation in this study. Only eligible
persons have been invited to participate. Persons who have had a
severe head or spinal injury that resulted in leakage of
cerebrospinal fluid (the fluid that surrounds and cushions the
brain) are not eligible to participate.

6. Number o f Subjects: 92 Total People will participate in the experiment.
7. Study Procedures: All research subjects will be spending the night in the sleep
laboratory for a diagnostic evaluation, which might include a
CPAP trial aimed at finding a proper level o f treatment (air
pressure) for obstructive sleep apnea, a routine procedure for
persons who have this sleep disorder. Some persons may not
receive a CPAP trial during the course of the sleep study if they
do not have obstructive sleep apnea or if the degree of their
illness does not clinically require CPAP treatment. The
diagnostic sleep study will occur immediately following each
subject’s participation in the research study. CPAP delivers a
constant stream of pressurized air through your nose, which
prevents you from stopping breathing during sleep. There will be
no change in the way that CPAP is normally used in the the Sleep
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Disorders Center of Alabama, Inc. or the HealthSouth Medical
Center Sleep Disorders Center (depending on which sleep
laboratory you are having your examination). You and others
people in the group that you are participating in will receive the
routine clinical care that is the current community standard of
care in a sleep disorders center that has been accredited by the
American Sleep Disorders Association. You will not be deprived
o f any preparations that are used to get people ready for their
sleep studies. Data from your sleep study and home CPAP use
(if you are prescribed CPAP) will be compared against persons
receiving a variation of normal laboratory procedures, which is
believed might make their adjustment to CPAP easier. All
persons will receive written information. Your participation will
not reduce or modify information that is normally gathered
during the course o f a sleep study. Finally, the proposed study is
not an experimental procedure, but rather is a variation of the
CPAP procedure, which has been designed, with the aim of
making adjustment to CPAP easier.
8. Benefits:

This study may benefit you in your adjustment to CPAP and will
further scientific knowledge in the field of sleep medicine
concerning the treatment o f obstructive sleep apnea syndrome.

9. Risks/Discomforts: One risk is that some persons report experiencing anxiety, which
may take the form claustrophobia, why wearing the CPAP mask.
In general, there is only one major reason that CPAP should not
be used for the treatment o f sleep apnea. CPAP should not be
used with persons who have suffered a very severe head or spinal
injury that caused leakage of cerebrospinal fluid (the fluid which
surrounds and cushions the brain). As mentioned above, persons
who have had an injury o f this nature are not eligible to
participate.
10. Right to Refuse:

You have the right to end your participation in this research study
at any point that you choose and for any reason that you might
have without penalty to yourself. Choosing to drop out of the
study will not affect the treatment that you will receive during
your sleep study tonight or at any other time regarding your sleep
apnea.

11. Privacy:

The results o f this study may be published in a research paper,
but your identity or the fact that you have participated in this
study will never be made available to public or any other agency.
Your participation in this research study will be kept confidential.
However, during the study, representatives from the US Food and
Drug Administration (FDA) will be allowed to review your
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medical records that relate to the study. The Baptist Health
System Human Research Review Board may also review these
records. The records will identify you only by your initials and
an assigned research study number, not by your name.
When you sign the consent document, you are giving your doctor
permission to release your research study medical records for
review. The representatives described in the paragraph above
will use these records only to carry out their obligations
associated with this study. Every effort will be made to ensure
that your study records are not used for any other purpose, or
given to anyone else, except when required by law.
12. Financial Information:

You will not be paid to participate in this study, and there
will be no cost to you for participating.
The Baptist Health System Inc, Sleep Disorder Center of
Alabama, and Mr. Jack Johnson have made no provision
for monetary compensation in the event of physical illness
and/or injury resulting from this research study. In the
event of such injury, medical treatment is available but is
not free of charge. There is no monetary (or other) form
of compensation for my participation in this study.
If you have any questions about compensation or medical
treatment for research-related injuries, contact G. Vernon
Pegram, Ph.D. or Mr. Jack Johnson at the Sleep Disorder
Center of Alabama at 599-1020.

13. Alternatives:

Currently, CPAP is the best treatment for sleep apnea
for most persons. Your doctor is available to discuss other
treatment options with you. The current study is not a treatment,
but rather an examination o f a way of helping people adjust to a
treatment that they might be prescribed by their doctors after they
experience CPAP in the laboratory during sleep.

14. Unforeseeable Risks:

15. Injurv/Illness:

There are no potential risks that a person might suffer
from resulting participation in this study.

If you have questions about this study or you experience any
unexpected adverse event (side effect) while you are participating
in this study, G. Vernon Pegram, Ph D. or Mr. Jack Johnson
should be contacted at (205) 599-1020 or (205) 934-7110. He
will be available to answer your questions before, during, and
after the study.

88

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

16. New Findings:

If any significant new findings occur during the course of the
study including problems that others who have participated have
experienced in the study, you will be informed of this by one of
the investigators listed above.

17. How to Learn More About Your Rights as a Reseach Subject:
If you have any questions about your rights as a research subject,
contact the Baptist Health System Human Research Review
Board, 800 Montclair Road, Birmingham, AL 35213, telephone
205/592-5700.
18. Signatures:

The study has been discussed with me and all my questions have
been answered. I may direct additional questions regarding study
specifics to the investigators. I agree to participate in the study
described above and acknowledge the investigator’s obligation to
provide me with a signed copy of the consent form.

Subject Signature

Date
The study subject has indicated to me that he/she is unable to
read. I certify that I have read this consent form to the subject
and explained that by completing the signature line above, the
subject has agreed to participate.

Signature o f Reader

Date
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Appendix D
Alton Ochsner Medical Foundation Informed Consent
Examination o f a Method for Increasing Adjustment to and Compliance with Nasal
Continuous Positive Airway Pressure (CPAP) in Persons with Obstructive Sleep Apnea
Syndrome
This study in not sponsored, and is a doctoral dissertation research project.
Principal Investigator: William F. Waters, Ph.D.
Sub-Investigators: Jack A. Johnson, Jr., MA and Mark Hurry, Ph.D.
You have been invited to participate in the clinical research study . Examination of a
Method for Increasing Adjustment to and Compliance with Nasal Continuous Positive
Airway Pressure (CPAP) in Persons with Obstructive Sleep Apnea Syndrome.
The doctors at Ochsner study the nature o f disease and attempt to develop improved
methods of diagnosis and treatment. This is called clinical research. To decide whether
or not you should agree to be part of this research study, you should understand enough
about its risks and benefits to make an informed judgment. This process is called
informed consent.
Purpose
The purpose of this study is to examine a method that may help people to adjust better to
nasal Continuous Positive Airway Pressure (called CPAP) treatment for sleep apnea.
Sleep apnea is a sleep disorder which means that a person ceases to breathe repeatedly for
a short periods o f time while asleep. You have been asked to participate in this study
because^ based on a review of your symptoms, your physician has determined that you
may be at significant risk of having sleep apnea. As part of your sleep study, you might
receive CPAP treatment if professionals in the sleep laboratory determine that you have
sleep apnea.
Procedure
You will be spending the night in the sleep laboratory for a diagnostic evaluation, which
could include a CPAP trial aimed at finding a proper level o f treatment (air pressure) for
obstructive sleep apnea, a routine procedure for persons who have this sleep disorder.
CPAP delivers a constant stream o f pressured air through your nose, which prevents you
from stopping breathing during sleep. You may not receive a CPAP trial during the
course o f the night if you do not have obstructive sleep apnea or if the degree of your
illness does not warrant CPAP treatment during the same night as your initial diagnostic
sleep study.
If you agree to participate in this research study, the diagnostic sleep study will occur
immediately after we have completed the procedures required for this research study.
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Subjects who agree to participate in this study will be randomly assigned to one of two
groups. This means that you will have a SO/SO chance of being placed in either of these
two groups. This method is similar to the flip of a coin.
If you are assigned to the first group, you will be asked to wear the CPAP mask with air
pressure before bedtime while you are not in bed and not attempting to fall asleep.
There will be no change in the way that CPAP is normally used in the Sleep Disorders
Center, Ochsner Clinic, Baton Rouge. The total time that you will be asked to wear the
CPAP mask with pressure is approximately 30 minutes, during which time you will
experience a range of gradually building CPAP pressures that are commonly experienced
during the course o f a sleep study with CPAP. You will experience four pressure settings
for exactly seven and a half minutes each. The pressure will be increased every seven and
a half minutes and will increase a total of three times before the trial comes to a
conclusion. During the time that you are wearing the CPAP mask, you may engage in
any relaxing activity that you choose, including watching television or reading. Data
from the sleep study and home CPAP use for the first several weeks you are using CPAP
(only if your are prescribed CPAP treatment) will be compared against persons receiving
the routine laboratory procedures.
If you are assigned to the second group, you will be asked to provide some additional
information in a Sleep Disorders Inventory about your sleep problem in addition to
receiving the routine clinical care that is currently the community standard of care in
centers specializing in the diagnosis and treatment of sleep disorders. Data from your
sleep study and home CPAP use for the first several weeks you are using CPAP (only if
your are prescribed CPAP treatment) will be compared against those persons who are in
the first group and are receiving a variation of the normal laboratory procedures.
You will receive written information about CPAP treatment for sleep apnea for
educational purposes. Your participation will not reduce or modify information that is
normally gathered during the course o f a sleep study. Finally, the proposed study is not
an experimental procedure, but rather is an examination of a variation of the CPAP
procedure that has been designed with the aim of evaluating its potential in making
adjustment to CPAP easier.
Benefits
This study may benefit you in your adjustment to CPAP and will further scientific
knowledge in the field o f sleep medicine concerning the treatment o f obstructive sleep
apnea syndrome with CPAP. No direct benefit to you may result from your
participation in this study.
Risks
One risk is that some persons experience anxiety, which may take the form of
claustrophobia, while wearing the CPAP mask. If this occurs, alert the investigator who
will be in the room with you during the procedure. In general, there is only one major
reason that CPAP should not be used for the treatment o f sleep apnea. CPAP should
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not be used in persons who have suffered a very severe head or spinal injury that caused
leakage o f cerebrospinal fluid (the fluid which surrounds and cushions the brain).
Persons who have experienced an injury of this nature are not eligible to participate.
You understand that Louisiana state law requires that participants in all clinical studies
such as this one be informed that any study (or procedure) may also result in death, brain
damage, quadripiegia (paralysis in all arms and legs), paraplegia (paralysis of both legs),
loss o f organ, loss o f arm or leg, loss of function of organ, loss of function o f an arm or
leg, and disfiguring scars.
Alternative Methods/Treatments
Currently, CPAP is clearly the best treatment for sleep apnea for most people. You do
not have to participate in this study in order to receive CPAP. Your doctor will also
discuss other treatment options with you, which range from weight loss to palatal
surgery.
The current study is not a treatment for sleep apnea, but rather an examination of a
method o f helping people adjust to CPAP after they experience CPAP in the laboratory
during sleep to prevent sleep apnea.
Payment for Participations and/or Reimbursement of Expenses
You will not be paid to participate in this study, and there will be no cost to you for
participating.
Additional Costs
There are no known additional or anticipated costs for participating in the study.
Compensation for Injury
You understand that in the event of related injury from the research procedures, medical
treatment, including hospitalization, if necessary for injuries or illness, is available. This
medical treatment and/or hospitalization not provided free of charge. No provision for
monetary compensation has been made in the event of an injury resulting from the
research.
Confidentiality
The confidentiality o f your records will be maintained to the extent consistent with the
law. Governmental agencies, such as the Food and Drug Administration, may review and
copy your records to ensure compliance with regulations and protocols. Additionally, the
sponsor and Ochsner authorized officials may review your records to ensure compliance.
You will not be identified in any reports or publications resulting from the study.
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Contact Information
You understand that should you have any questions about the study or suffer any injury
that you feel may be related to the study, upi should contact the Responsible
Investigator William F. Waters, Ph.D. or his associate, Jack A. Johnson, Jr., MA by
calling (225) 761-5852. You also understand that you may take any problem or any
question concerning your rights to the Office of Research Administration, Fifth Floor,
Brent House, Telephone (504) 842-3562.
Safeguards
Whereas no assurance can be made concerning the results that may be obtained
(since results from a clinical research study cannot be predicted), your
physician, acting as Responsible Investigator, will take every precaution
consistent with the best medical practice;
By signing this consent form you have not waived any of your legal rights or
released this institution from liability for negligence.
Participation in this study is voluntary. You may revoke your consent and
withdraw from this study at any time without any penalty or loss o f benefits to
which you are otherwise entitled;

You have disclosed to your doctors all o f your past and present diseases and
allergies of which you are aware and all drugs and medications which you are
presently using.
Additional Information
If any significant new findings occur during the course of the study, including problems
that others who have participated have experienced in the study, you will be informed
o f this by one of the investigators above. Although not anticipated, the investigators
reserve the right to eliminate any subject from participating fiirther regardless of a
subject’s consent. Circumstances under which this might occur would include
terminating the CPAP trial early if continuation of the trial would prevent you from
starting your sleep study on time during the night o f your participation. There are no
consequences o f any kind for a subject who wishes to voluntarily withdraw from the
study. The procedure for withdrawing from the study is to 1) inform the investigator
during the course o f your participation during the experiment or 2) to contact one of the
investigators at the telephone number listed above if you wish to withdraw at a later
time.
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Statement o f Voluntary Agreement to Participate
The procedure(s) involved, expected duration o f participation, alternative
methods/treatments, and possible benefits, discomforts, risks, and adverse effects have
been explained to me in language I understand as set forth above by Dr. William F.
Waters or his representative, Jack A. Johnson, Jr., MA I have been given the time to ask
questions, which have been answered to my satisfaction. I have been given a copy o f this
consent for my information and records. I voluntarily consent to participate in this
investigation.

Patient
Date

Patient ID Number

Witness
Date

Physician (Responsible Investigator)

Date
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Appendix E
Sleep Disorders Inventory
William F Waters, P h D , ABPP, BCSS
Director, Ochsner Clinic of Baton Rouge, Sleep Disorders Center
and
Professor, Department of Psychology, Louisiana State University
Please provide the following information:
Name: __________________________________Clinic Number____________________
Date: ____________ Age:_________Birth Date:_____________W eight:___________
Height:
BMI ________

Instructions: The following questions will help us understand any sleep problems you
may have. Please answer all o f the questions to the best of your ability. For some
questions, you should circle YES if the item is true for you or NO if the item does not
apply to you. For other questions, a space is provided for you to write a number, such as
how many minutes it takes you to fall asleep. For all questions, give an answer that is the
closest to the truth as you know it. For some questions, you may have to ask someone
who has seen you sleep; if no one has seen you sleep, write DK (don’t know).

1. What is your primary sleep problem?
How long have you had that problem?

No. Years;

No. Months;__ No. Weeks

2. At what time do you usually turn out the lights to go to sleep?........................ ..............
At what time do you usually wake up for the next day?..................................................
3. How many minutes does it usually take you to fall asleep?............................................
4. How many nights a week do you get 9 or more hours sleep?.......................... ...............
How many nights a week do you get 8 hours sleep?......................................................
How many nights a week do you get 7 hours sleep?......................................................
How many nights a week do you get 6 hours sleep?.......................................................
How many nights a week do you get 5 or less hours sleep?............................ ..............
5. Do you take 30 minutes or more to fall asleep, more than once a week?
YES NO
If YES: How many nights does this happen each week?................................ ...............
On nights when you have this problem how many minutes does it take you to fall
asleep?................................................................................................................ ...............
On nights when you have this problem, how many hours do you sleep?
..............
6. Do you wake up during the night and take 20 minutes or more to regain sleep, more
than once a week?.............................................................................................YES NO
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If YES: How many nights does this happen each week?................................ ...............
On average, how many times does this happen each night?
..............
How many minutes does it take you to fall back asleep each time? . _______
On nights when you have this problem, how many hours do you sleep?_____
7. Do you often wake up in the morning before your scheduled wake time, and cannot
go back to sleep?
YES NO
If YES: How many nights each week do you have this problem?................... ..............
On nights when you have this problem, how many hours do you sleep?_____
8. Do you often fall asleep at inappropriate times or places during the day because you
are not getting
enough sleep?.....................................................................................................YES NO
9. Do you often have trouble functioning during the day because you are not getting
enough sleep?
YES NO
10. On nights when you do get a full night’s sleep, do you stiU:
• Have trouble waking up, or wake up feeling unrefreshed?
YES NO
• Fall asleep involuntarily during the day, but only when somewhat unstimulated?. .
YES NO
If YES, check each example that applies to you: While watching TV
,
while reading a book
, while a passenger in a car
, while in a traffic
jam
• Fall asleep involuntarily during the day, even when doing something important or
stimulating?
YES NO
If YES, check each example that applies to you: While driving_____ , while
doing your work
, while talking to others
.
• Have trouble functioning during the day?.....................................................YES NO
11. Do you ever sleep 12 or more hours and still wake up unrefreshed?................ YES NO
If YES, do you still need to nap during the day?
YES NO
If YES, how many times a month does this occur?......................................... ...............
12. How many nights per month do you:
Snore loudly and persistently
Thrash about while asleep (but are not dreaming)
Gasp or snort while asleep
Stop breathing while asleep or wake up in the night and feel unable to breathe
How many mornings a month do you awaken with a headache?
13. Does it often take you longer to fall asleep because your legs feel restless or odd in
bed?...................................................................................................................... YES NO
If YES: Does moving your legs in bed, or getting up and moving around help you
fall asleep?............................................................................................................YES NO
How many nights per month do your legs feel this way?................................ ................
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14. Do you often wake from a sound sleep repeatedly because your legs jerk?.. YES NO
If YES . Are your leg movements frequent and regular?
YES NO
How many nights per month does this happen?...............................................
15. Have sleep attacks in which you suddenly and uncontrollably fall asleep? . ..YES NO
If YES: How many minutes do you sleep (nap) when you have such an attack?____
Do you awaken from your nap feeling refreshed?
YES NO
How many times per month does this happen?................................................
16. When you are startled, emotional, excited or happy do you often experience extreme
weakness (for example, in your legs) or drop things?
YES NO
17. When you are startled, emotional, or excited do you often collapse or fall?.. YES NO
If YES: Are you still aware o f your surroundings?
YES NO
18. As you fall asleep or wake up, do you often see things that are not there?.. YES NO
If YES: Are the things you see very clear and realistic?
YES NO
How many times each month does this happen?............................................
19. As you fall asleep or wake up, are you often unable to move (paralyzed)? .. YES NO
If YES: How many times each month?...........................................................................
18. How many nights have nightmares awakened you in the last month?
..............
If ANY: How intense are they? (l=Mild, 2=Frightening, 3=Terrifying) . . . . _______
19. Do you often move violently during your sleep while dreaming, and sometimes even
hurt yourself or your partner by accident or fall out o f bed?
YES NO
If YES: How many times in the last month has this happened?..................... ...............
20. Do you often wake up from a deep sleep sweating, your heart beating fast or
pounding, with a feeling o f fear but with no memory of a dream?
YES NO
If YES: How many times in the last month has this happened?.................... ...............
How intense is this experience? (l=Mild, 2=Frightening, 3=Terrifying)_____
Does this ever happen during the day?................................................ YES NO
21. Do you often grind your teeth in your sleep?.................................................... YES NO
22. How many times each night do you wake up specifically to use the bathroom?______
23. How many nights each week do you wake up with indigestion or heartburn?._______
24. Do you often eat your last meal or a large snack within 2 hours o f bedtime? YES NO
25. Do you often exercise vigorously within an hour of bedtime?.........................YES NO
26. How many nights each month do you use alcohol within 2 hours o f bedtime._______
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27. How many nights each month do you use alcohol to help you fall asleep?.. . . ____
28. How many caffeinated beverages do you drink in a day?................................. .........
29. How many days a week do you drink caffeinated beverages after 7 p.m .?. . . ____
30. How often is your sleep problem caused or made worse by physical discomfort or
pain? (check one): Never
Rarely
Sometimes
Often_____
Most or All of the Time
31. Do you ever work night shifts (any 8-12 hour shift starting after 6 pm )?
YES NO
If YES: How many nights per month? .......................................................................
32. Do you often work at home after 8 pm?
YES NO
If YES: How many nights per w eek?...........................................................................
33. Do you deliberately sleep less in order to do other things?.............................. YES NO
If YES: How many nights per week?..............................................................................
How many hours per night?............................................................... ...............
34. On weekends or your days off, do you often sleep more than 1 hour later than your
usual wake up time?........................................................................................... YES NO
35. Do you often go to bed earlier to make up for lost or unrefreshing sleep?. . . YES NO
36. Do you often wake up later to make up for lost or unrefreshing sleep?........... YES NO
37. Do you take naps?............................................................................................. YES NO
If YES: How many times each week do you take naps?.................................................
How many minutes are your naps, on average?...............................................
Do you awaken from your naps refreshed?........................................YES NO
38. Do you often lose sleep because your bed partner disturbs you at night?

YES NO

39. Is your sleep often disturbed by environmental factors, such as traffic, neighbors or
family members?................................................................................................ YES NO
40. Do you often lose sleep because your bedroom is not dark enough at night? YES NO
41. Do you often lose sleep because your bedroom temperature is not comfortable enough
at night?...............................................................................................................YES NO
42. Do you usually sleep better when you sleep away from home?........................ YES NO
43..When you try to sleep, does worrying or problem solving often keep you awake?.. . .
........................................................................................................................... YES NO
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44. Do you often worry, in bed, about getting enough sleep to function the next day? . . . .
........................................................................................................................... YES NO
45. Do you often get frustrated and angry, in bed, about not getting to sleep?... YES NO
46. Do you worry too much in general?.................................................................YES NO
47. Have you been under noteworthy stress recently?...........................................YES NO
48. Check if you are currently diagnosed with:___ depression____ an anxiety disorder
49. Have you recently taken any prescription or over-the-counter medication for sleep
problems?......................................................................................................... YES NO
If YES: How many nights a week do you usually take this medication? . . . _______
How many months have you been taking this medication?
..............
50. Do you take any medications that contain caffeine or other stimulants, such as allergy
medications, nasal decongestants, or pain killers?............................................YES NO
If YES: How many minutes or hours before trying to sleep do you take them?______
51. Please list all prescription and over-the-counter medications you are now taking, and
what each is for:
MEDICATION
CONDITION
MEDICATION
CONDITION

52. Please list any medications you have recently stopped taking, and what each was for:
MEDICATION
CONDITION
MEDICATION
CONDITION

You may write any additional information that you think could be helpful in the space
below, or on the back o f this page:
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Appendix F
Correlation Coefficients for PSG Variables: Split-Night
Variable
SOL
SE
%l

SOL
—

SE
T s iT
___

%i

% sw s

REM

STA

-.17

-.25

.49”

No.
Awake
.15

-.52"

-.02

.32*

-.45"

-.53"

_______

-.19

-.25

..74“

..62"

_______

-.02

-.11

-.19

-.22

- 19

41W
*

%SWS
REM
STA

—

No.
Awake
Note. * significant at .05 level, 2-tailed, ** significant at .01 level, 2-tailed.
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Appendix G
Correlation Coefficients for PSG Variables: Full-Night
%1

%sws

REM

STA

.42"

-.23

-.53*

.39"

No.
Awake
.21

-.51“

.18

.44

-.33“

00
1*

-31*

-.56*

.69“

67”

%sws

.28

-.14

-.33*

REM

_______

-04

-.53*

_______

.42“

Variable
SOL

SOL

SE
-.59

•
•

SE
%l

-

-

.

STA

No.
Awake
Note. * significant at .05 level, 2-tailed, ** significant at .01 level, 2-tailed.
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Appendix H
Correlation Coefficients Relevant to an Examination of CPAP Use
Variable
Gender
BM1
A+Hl

Gender
—

BMI

A+HI

Accept

-.01

-.36"

—

Titration

.06

CPAP
Use
-.33“

.21

.01

.16

-.14

—

.11

.22

-.40"

—t

.05

Accept

—

CPAP
Use
Titration

.54"

-.32*

Note. * two-tailed significance o f p < .05, ** two-tailed significance of p < .01,t cannot
be calculated because Use is dependent upon Acceptance of CPAP.
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Vita
Jack A. Johnson, Jr. was born in Atlanta, Georgia and grew up in a suburb
Knoxville, Tennessee. He lived in Knoxville until he was 24 years old and spent too
much time playing guitar and Super Nintendo with friends from college. Jack moved to
Baton Rouge in the fall of 1994 to begin his graduate studies in psychology at the
Louisiana State University and Agricultural and Mechanical College. He also spent two
long and boring years in Birmingham, Alabama where he and his wife, DeAnn M.
Johnson, completed psychology internships at the University of Alabama at Birmingham
psychology consortium. As you probably guessed because he is from the southern United
States, Jack is a rabid college football fan and follows the Tennessee Volunteers and the
Tigers almost every Saturday from September through the first week of January.
Additionally, Jack and his wife enjoy the New Orleans Saints’ games on Sundays. You
might be surprised to know that Jack’s true passion in life is not psychology but is history.
Jack is particularly interested in the sacrifice and courage of those who fought in World
War II. American history is another area o f great interest for Jack, and he plans to spend
much of his free time reading about noteworthy events in history. Also, Jack has
aspirations to write about history, and has plans to explore writing a book about men from
Louisiana who served in the United States Merchant Marines during World War II.
Music is another area of interest for Jack, and he wrote the passage you are now reading
while listening to the Red Hot Chili Peppers’ Blood Sugar Sex Magic. Aerosmith,
AC/DC, and Led Zeppelin are long time favorites of his and helped ease the pain of
completing graduate school. Finally, Jack’s life history would not be complete without
mentioning his loyal and loving cat Claire, known to her friends as Swiggums. She
particularly likes spending quality time with her family, and is generally one cool cat.
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